<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">CAT</journal-id>
<journal-id journal-id-type="hwp">spcat</journal-id>
<journal-id journal-id-type="nlm-ta">Clin Appl Thromb Hemost</journal-id>
<journal-title>Clinical and Applied Thrombosis/Hemostasis</journal-title>
<issn pub-type="ppub">1076-0296</issn>
<issn pub-type="epub">1938-2723</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1076029611412362</article-id>
<article-id pub-id-type="publisher-id">10.1177_1076029611412362</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Reviews</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Prevention of Deep Vein Thrombosis and Pulmonary Embolism in Patients With Stroke</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Field</surname>
<given-names>Thalia S.</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-1076029611412362">1</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Hill</surname>
<given-names>Michael D.</given-names>
</name>
<degrees>MD, MSc, FRCPC</degrees>
<xref ref-type="aff" rid="aff2-1076029611412362">2</xref>
<xref ref-type="corresp" rid="corresp1-1076029611412362"/>
</contrib>
</contrib-group>
<aff id="aff1-1076029611412362"><label>1</label>Division of Neurology, Faculty of Medicine, University of British Columbia, Vancouver, BC Canada</aff>
<aff id="aff2-1076029611412362"><label>2</label>Departments of Clinical Neurosciences, Medicine, Rardiology and Community Health Sciences, Hotchkiss Brain Institute, Faculty of Medicine, University of Calgary, Calgary, AB Canada</aff>
<author-notes>
<corresp id="corresp1-1076029611412362">Michael D. Hill, Calgary Stroke Program, Department of Clinical Neurosciences, Hotchkiss Brain Institute, University of Calgary, Foothills Hospital, Rm 1242A, 1403 29th Streeet NW, Calgary, Alberta, T2N 2T9, Canada. Email: <email>michael.hill@ucalgary.ca</email>
</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>1</month>
<year>2012</year>
</pub-date>
<volume>18</volume>
<issue>1</issue>
<fpage>5</fpage>
<lpage>19</lpage>
<permissions>
<copyright-statement>© SAGE Publications 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>Venous thromboembolism (VTE), encompassing deep venous thrombosis and pulmonary embolism, is a potentially fatal but preventable complication of stroke. Reported rates of VTE after stroke have decreased over the last four decades, possibly due to the implementation of stroke units, early mobilization and hydration, and increased early use of antiplatelets. Additional means of thromboprophylaxis in stroke include mechanical methods (ie, compression stockings) to prevent venous stasis and medical therapy including antiplatelets, heparins, and heparinoids. Risk of VTE must be balanced by potential risk of hemorrhagic complications from pharmacotherapy. Unfractionated heparin, low-molecular-weight heparin (LMWH), and danaparoid are acceptable options for chemoprophylaxis though none have shown superior efficacy for VTE prevention without an associated increase in major hemorrhage. The efficacy and timing of pharmacological thromboprophylaxis in hemorrhagic stroke are not well defined. Graduated compression stockings are associated with an increased rate of adverse events and are not recommended and intermittent pneumatic compression stockings require further investigation.</p>
</abstract>
<kwd-group>
<kwd>stroke</kwd>
<kwd>ischemic stroke</kwd>
<kwd>intracerebral hemorrhage</kwd>
<kwd>subarachnoid hemorrhage</kwd>
<kwd>venous thromboembolism</kwd>
<kwd>pulmonary embolism</kwd>
<kwd>deep venous thrombosis</kwd>
<kwd>prophylaxis</kwd>
<kwd>heparin</kwd>
<kwd>low-molecular-weight heparin</kwd>
<kwd>direct thrombin inhibitors</kwd>
<kwd>antiplatelet</kwd>
<kwd>graduated compression stockings</kwd>
<kwd>intermittent pneumatic compression devices</kwd>
<kwd>electrical stimulation</kwd>
</kwd-group><custom-meta-wrap>
<custom-meta>
<meta-name>cover-date</meta-name>
<meta-value>January/Febraury 2012</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<sec id="section1-1076029611412362">
<title>Introduction</title>
<p>Venous thromboembolism (VTE) encompasses both deep vein thrombosis (DVT) and pulmonary embolism (PE). The incidence of VTE among patients with stroke is high, and PE remains the third-highest cause of case fatality in stroke.</p>
<p>Stroke places patients at high risk of VTE. Immobility is generally a key risk factor for VTE and as many as two thirds of patients will be immobile or require assistance with walking immediately after their stroke. A third will be nonambulatory or require assistance at 3 months.<sup><xref ref-type="bibr" rid="bibr1-1076029611412362">1</xref>,<xref ref-type="bibr" rid="bibr2-1076029611412362">2</xref></sup> Immobility due to stroke may be compounded by deconditioning and by comorbidities including dementia, arthritis, and peripheral vascular disease.<sup><xref ref-type="bibr" rid="bibr3-1076029611412362">3</xref></sup> Systemic inflammation from cerebral injury<sup><xref ref-type="bibr" rid="bibr4-1076029611412362">4</xref><xref ref-type="bibr" rid="bibr5-1076029611412362"/>–<xref ref-type="bibr" rid="bibr6-1076029611412362">6</xref></sup> and infectious complications may also contribute to thrombosis risk.</p>
<p>Antithrombotic therapy been widely investigated as a means of thromboprophylaxis alongside nonpharmacologic interventions including mobilization, hydration, and mechanical methods. In addition to being a major risk factor for VTE, stroke is also a major risk factor for intracranial bleeding or, in the case of hemorrhagic stroke, hematoma expansion.</p>
<p>The weighing of the benefits of thromboprophylaxis against the risks of hemorrhage is an ever-present challenge for those involved in post-stroke care and necessitates a careful assessment of the available evidence.</p>
<sec id="section2-1076029611412362">
<title>Methods</title>
<p>A literature search (PubMed) was performed to locate relevant articles and studies pertaining to the incidence of VTE in stroke and trials of thromboprophylaxis in stroke. The reference lists of relevant articles were then hand-searched for other references. Relevant articles also underwent a “cited reference search” (ISI Web of Science). Studies that were not in English language or published in abstract form only were excluded. Specific search terms included “venous thromboembolism,” “DVT,” “deep venous thrombosis,” “pulmonary embolism,” “stroke,” ischemic stroke,” “intracerebral hemorrhage,” “ICH,” and “subarachnoid hemorrhage,” “prophylaxis,” “thromboprophylaxis,” “physical,” “mechanical,” and “electrical stimulation.”</p>
</sec>
<sec id="section3-1076029611412362">
<title>Epidemiology</title>
<p>Most DVT after stroke is asymptomatic. Reported incidence of VTE after stroke varies on the timing of screening and sensitivity of the screening modality.<sup><xref ref-type="bibr" rid="bibr7-1076029611412362">7</xref></sup>
</p>
<p>Studies conducted prior to the era of routine prophylaxis report a post-stroke deep venous thrombosis (DVT) rate of 45% to 75% detected by <sup>125</sup>I-fibrinogen scanning.<sup><xref ref-type="bibr" rid="bibr8-1076029611412362">8</xref><xref ref-type="bibr" rid="bibr9-1076029611412362"/>–<xref ref-type="bibr" rid="bibr10-1076029611412362">10</xref></sup>
</p>
</sec>
<sec id="section4-1076029611412362">
<title>Ischemic Stroke</title>
<p>The majority of studies that report thrombotic complications of stroke does not distinguish between ischemic and hemorrhagic index events. The reported incidence of clinically detected DVT in ischemic stroke ranges from 1% to 1.6%, whereas methods that screen for asymptomatic thrombi report a much higher incidence. Incidence detected by fibrinogen scanning or venography is 28% to 50%, and by Doppler US, 6.9% to 30%. Rates of clinically detected PE vary from 0% to 6.6% after 2 weeks, and up to 8% after 3 months. (<xref ref-type="table" rid="table1-1076029611412362">Table 1</xref>, <xref ref-type="table" rid="table2-1076029611412362">2</xref>

)</p>
<table-wrap id="table1-1076029611412362" position="float">
<label>Table 1.</label>
<caption>
<p>Incidence of Venous Thromboembolism After Acute Ischemic Stroke in the Absence of Anticoagulation</p>
</caption>
<graphic alternate-form-of="table1-1076029611412362" xlink:href="10.1177_1076029611412362-table1.tif"/>
<table>
<thead>
<tr>
<th align="left">Author</th>
<th align="left">Year</th>
<th align="left">Antiplatelets or Mechanical Prophylaxis</th>
<th align="left">N</th>
<th align="left">DVT Incidence</th>
<th align="left">Screening Modality for Asymptomatic DVT</th>
<th align="left">PE Incidence</th>
<th align="left">Screening for Asymptomatic PE</th>
<th align="left">Time to Enrollment</th>
<th align="left">Duration of Followup</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left">Turpie<sup><xref ref-type="bibr" rid="bibr11-1076029611412362">11</xref></sup>
</td>
<td align="left">1987</td>
<td align="left">–</td>
<td align="left">25</td>
<td align="left">28%</td>
<td align="left">Regular <sup>125</sup>I fibrinogen scanning, plethysmography, then venography if positive</td>
<td align="left">8%</td>
<td align="left">Clinical</td>
<td align="left">Within 7days of stroke</td>
<td align="left">3 months</td>
</tr>
<tr>
<td align="left">Prins<sup><xref ref-type="bibr" rid="bibr12-1076029611412362">12</xref></sup>
</td>
<td align="left">1989</td>
<td align="left">–</td>
<td align="left">30</td>
<td align="left">50%</td>
<td align="left">Daily <sup>125</sup>I fibrinogen scanning then venography if positive</td>
<td align="left">6.6%</td>
<td align="left">Clinical</td>
<td align="left">Within 72 hours of stroke</td>
<td align="left">14 days</td>
</tr>
<tr>
<td align="left">Sandset<sup><xref ref-type="bibr" rid="bibr13-1076029611412362">13</xref></sup>
</td>
<td align="left">1990</td>
<td align="left">–</td>
<td align="left">50</td>
<td align="left">34%</td>
<td align="left">Unilateral venography of paretic limb</td>
<td align="left">4%</td>
<td align="left">Clinical</td>
<td align="left">Within 72hours of stroke</td>
<td align="left">28 days</td>
</tr>
<tr>
<td align="left">Kay<sup><xref ref-type="bibr" rid="bibr14-1076029611412362">14</xref></sup>
</td>
<td align="left">1995</td>
<td align="left">Antiplatelet use “discouraged”</td>
<td align="left">105</td>
<td align="left">1%</td>
<td align="left">Clinical</td>
<td align="left">0%</td>
<td align="left">Clinical</td>
<td align="left">Within 48 hours of stroke</td>
<td align="left">10 days</td>
</tr>
<tr>
<td align="left">IST<sup><xref ref-type="bibr" rid="bibr15-1076029611412362">15</xref></sup>
</td>
<td align="left">1997</td>
<td align="left">4858 aspirin, 4860 no aspirin</td>
<td align="left">9718</td>
<td align="left">N/A</td>
<td align="left">N/A</td>
<td align="left">0.8%</td>
<td align="left">Clinical</td>
<td align="left">Within 48 hours of stroke</td>
<td align="left">14 days</td>
</tr>
<tr>
<td align="left">TOAST<sup><xref ref-type="bibr" rid="bibr16-1076029611412362">16</xref></sup>
</td>
<td align="left">1998</td>
<td align="left">No antiplatelets for 7days post-stroke</td>
<td align="left">628</td>
<td align="left">0.03% by 7 days, 0.05% by 10 days, 1.6% by 3 mo</td>
<td align="left">Clinical</td>
<td align="left">0.02% by 7 days, 0.03% by 10 days, 0.06% by 3 mo</td>
<td align="left">Clinical</td>
<td align="left">Within 24 hours of stroke</td>
<td align="left">3 months</td>
</tr>
<tr>
<td align="left">Muir<sup><xref ref-type="bibr" rid="bibr17-1076029611412362">17</xref></sup>
</td>
<td align="left">2000</td>
<td align="left">Antiplatelets; 67% randomized to compression stockings</td>
<td align="left">98</td>
<td align="left">9.3% at enrollment, 11.3% at days 7 ± 2</td>
<td align="left">Doppler US at enrollment and at days 7 ± 2</td>
<td align="left">N/A</td>
<td align="left">N/A</td>
<td align="left">Within 72 hours of stroke</td>
<td align="left">7 ± 2 days</td>
</tr>
<tr>
<td align="left">Kelly<sup><xref ref-type="bibr" rid="bibr18-1076029611412362">18</xref></sup>
</td>
<td align="left">2004</td>
<td align="left">Antiplatelets, compression stockings</td>
<td align="left">102</td>
<td align="left">40.2% any VTE, 17.7% proximal DVT</td>
<td align="left">MR DTI at days 7-14, days 21-28 post-stroke, weekly clinical assessment</td>
<td align="left">11.8%</td>
<td align="left">MR DTI at d 7-14, d 21-28 post stroke, Weekly clinical assessment</td>
<td align="left">Within 7 days post-stroke</td>
<td align="left">Mean 21.0 days (SD, 5.9)</td>
</tr>
<tr>
<td align="left">Skaf<sup><xref ref-type="bibr" rid="bibr19-1076029611412362">19</xref></sup>
</td>
<td align="left">2005</td>
<td align="left">–</td>
<td align="left">14,109,000</td>
<td align="left">0.74% “DVT”, 1.17% “VTE”</td>
<td align="left">Hospital discharge data</td>
<td align="left">0.51% “PE”</td>
<td align="left">Hospital discharge data</td>
<td align="left">–</td>
<td align="left">–</td>
</tr>
<tr>
<td align="left">De Silva<sup><xref ref-type="bibr" rid="bibr20-1076029611412362">20</xref></sup>
</td>
<td align="left">2006</td>
<td align="left">Antiplatelets, no anticoagulants before first Doppler, 63% with compression stockings</td>
<td align="left">111</td>
<td align="left">30% at d 7-10, 45% at days 25-30</td>
<td align="left">Doppler US at 7-10 days, 25-30 days post-stroke</td>
<td align="left">1%</td>
<td align="left">Not discussed</td>
<td align="left">7-10 days post-stroke</td>
<td align="left">6 months post-stroke</td>
</tr>
<tr>
<td align="left">Tan<sup><xref ref-type="bibr" rid="bibr21-1076029611412362">21</xref></sup>
</td>
<td align="left">2007</td>
<td align="left">Antiplatelets and compression stockings in some</td>
<td align="left">29</td>
<td align="left">6.9%</td>
<td align="left">Doppler US at 48 hours, 7 days, and 30 days post-stroke</td>
<td align="left">N/A</td>
<td align="left">N/A</td>
<td align="left">48 hours post-stroke</td>
<td align="left">30 days post-stroke</td>
</tr>
</tbody>
</table>
</table-wrap>
<table-wrap id="table2-1076029611412362" position="float">
<label>Table 2.</label>
<caption>
<p>Pooled Estimate of Incidence of Venous Thromboembolism After Acute Ischemic Stroke by Screening Modality</p>
</caption>
<graphic alternate-form-of="table2-1076029611412362" xlink:href="10.1177_1076029611412362-table2.tif"/>
<table>
<thead>
<tr>
<th>
</th>
<th align="center" colspan="3">DVT</th>
<th align="center" colspan="3">PE</th>
</tr>
<tr>
<th>Screening Method</th>
<th align="center">n</th>
<th>Pooled Incidence<sup><xref ref-type="table-fn" rid="table-fn2-1076029611412362">
a
</xref></sup>
</th>
<th align="center">Range</th>
<th align="center">n</th>
<th>Pooled Incidence<sup>a</sup>
</th>
<th>Range</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical/postmortem</td>
<td>733</td>
<td align="center">1.5%</td>
<td align="center">1%-1.6%</td>
<td align="center">949</td>
<td align="center">1.4%</td>
<td>0%-8%</td>
</tr>
<tr>
<td>
<sup>125</sup>I fibrinogen scanning and/or venography</td>
<td>105</td>
<td align="center">37%</td>
<td align="center">28%-50%</td>
<td align="center">–</td>
<td align="center">–</td>
<td>
</td>
</tr>
<tr>
<td>Doppler US</td>
<td>238</td>
<td align="center">26%</td>
<td align="center">6.9%-30%</td>
<td align="center">–</td>
<td align="center">–</td>
<td>
</td>
</tr>
<tr>
<td>MRDTI</td>
<td>102</td>
<td align="center">18%</td>
<td>18% (proximal only)</td>
<td align="center">102</td>
<td align="center">12%</td>
<td align="center">12%</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-1076029611412362">
<p>Abbreviations: DVT, deep vein thrombosis; PE, pulmonary embolism; MRDTI, magnetic resonance direct thrombus imaging.</p>
</fn>
<fn id="table-fn2-1076029611412362">
<p>
<sup>a</sup> Data from IST and Skaf excluded, given the extremely large number of participants and high probability of underreported events.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>In a 2004 study where patients with ischemic stroke received care per the UK guidelines, at 3 weeks there was 3% incidence of clinically detectable DVT and 18% incidence of DVT detected by magnetic resonance direct thrombus imaging (MRDTI). There was an 11.8% incidence of PE on MRDTI and a 5% incidence of clinically detected PE.<sup><xref ref-type="bibr" rid="bibr18-1076029611412362">18</xref></sup> Using the criteria of oxygen saturation ≤92% and respiratory rate of &gt;20 minutes as being “symptomatic” for PE, only 3% of clinically evident PE were detected by the attending medical team.<sup><xref ref-type="bibr" rid="bibr18-1076029611412362">18</xref></sup> In the CLOTS-1 trial, in which the majority of participants (91%) had an ischemic event, 10.5% of controls receiving routine care (including antiplatelets or anticoagulants) without graduated compression stockings (GCS) had DVT at 30 days postevent by Doppler US, a less sensitive screening technique. Incidence of PE on imaging<sup><xref ref-type="bibr" rid="bibr22-1076029611412362">22</xref></sup> or at autopsy was 1.3%</p>
</sec>
<sec id="section5-1076029611412362">
<title>Intracerebral Hemorrhage</title>
<p>Overall, reported rates of VTE in intracerebral hemorrhage (ICH) range from 16% to 21% for DVT detected by regular Doppler US screening<sup><xref ref-type="bibr" rid="bibr23-1076029611412362">23</xref><xref ref-type="bibr" rid="bibr24-1076029611412362"/>–<xref ref-type="bibr" rid="bibr25-1076029611412362">25</xref></sup> and from 0.4% to 2% for clinically diagnosed PE.<sup><xref ref-type="bibr" rid="bibr26-1076029611412362">26</xref></sup> In controls from 3 trials of recombinant factor VIIa for ICH, rates of clinically diagnosed DVT and PE were 1% to 3% and 1% to 2%, respectively.<sup><xref ref-type="bibr" rid="bibr23-1076029611412362">23</xref></sup>
</p>
<p>Some studies directly comparing the rates of VTE between patients with ischemic and hemorrhagic strokes suggest that VTE may occur more frequently in ICH. This may be a result of more severe weakness, depressed level of consciousness, and avoidance of routine antiplatelets in the ICH group.<sup><xref ref-type="bibr" rid="bibr27-1076029611412362">27</xref></sup> A retrospective cohort of administrative data from an American tertiary care center found a higher rate of DVT and PE in ICH than in ischemic stroke (DVT 1.9% of 1126 ICH vs 0.5% of 15 599 ischemic stroke; PE 0.4% vs 0.1%).<sup><xref ref-type="bibr" rid="bibr28-1076029611412362">28</xref></sup> A larger retrospective study of American administrative data from the National Hospital Discharge Survey found the same (DVT 1.37% of 1 606 000 ICH vs 0.74% of 14 109 000 ischemic stroke; PE 0.68% vs 0.51%).<sup><xref ref-type="bibr" rid="bibr19-1076029611412362">19</xref></sup> A substudy of patients with hemorrhagic stroke initially included in the International Stroke Trial found that patients with ICH had a higher rate of clinically diagnosed PE than patients with ischemic stroke (1.3% vs 0.7% <italic>P</italic> = .06) when controlling for disease severity.<sup><xref ref-type="bibr" rid="bibr29-1076029611412362">29</xref>,<xref ref-type="bibr" rid="bibr30-1076029611412362">30</xref></sup>
</p>
</sec>
<sec id="section6-1076029611412362">
<title>Subarachnoid Hemorrhage</title>
<p>There are scant data specific to patients with aneurysmal subarachnoid hemorrhage (SAH) in the neurosurgical literature regarding prevention or prevalence of VTE. The rate of DVT detected by Doppler US was 14% in 1 series of patients with SAH without prophylaxis; the reported rate<sup><xref ref-type="bibr" rid="bibr31-1076029611412362">31</xref><xref ref-type="bibr" rid="bibr32-1076029611412362"/><xref ref-type="bibr" rid="bibr33-1076029611412362"/>–<xref ref-type="bibr" rid="bibr34-1076029611412362">34</xref></sup> of PE ranges from less than 1% to 2%.</p>
</sec>
<sec id="section7-1076029611412362">
<title>Morbidity and Mortality</title>
<p>Pulmonary embolism carries a mortality rate<sup><xref ref-type="bibr" rid="bibr35-1076029611412362">35</xref></sup> of 30% to 50% and causes 10% to 25% of case fatality in stroke. It is the third leading cause of post-stroke mortality after the stroke itself and secondary infection.<sup><xref ref-type="bibr" rid="bibr36-1076029611412362">36</xref><xref ref-type="bibr" rid="bibr37-1076029611412362"/>–<xref ref-type="bibr" rid="bibr38-1076029611412362">38</xref></sup> The rate of clinically evident PE after DVT ranges from 15% to 35%.<sup><xref ref-type="bibr" rid="bibr9-1076029611412362">9</xref>,<xref ref-type="bibr" rid="bibr35-1076029611412362">35</xref></sup> Pulmonary embolism rates were highest 2 to 4 weeks after stroke in 1 series. Pulmonary embolism, however, may occur many weeks post-stroke, which heralds the common clinical problem of how long to provide prophylactic therapy.<sup><xref ref-type="bibr" rid="bibr36-1076029611412362">36</xref></sup> A retrospective series found 50% of 30 patients with stroke having PE presented with sudden death.<sup><xref ref-type="bibr" rid="bibr39-1076029611412362">39</xref></sup>
</p>
<p>Thrombi form in the proximal or distal limb; PE associated with proximal DVT is less frequent but more likely to be clinically evident and carries higher morbidity and mortality.<sup><xref ref-type="bibr" rid="bibr35-1076029611412362">35</xref></sup> Two thirds of DVT after stroke were below knee,<sup><xref ref-type="bibr" rid="bibr40-1076029611412362">40</xref></sup> explaining why most DVT associated with stroke is asymptomatic.</p>
<p>In a nonstroke population, the risk of proximal extension of distal DVT is 1 in 6; one study found a 20% rate after stroke.<sup><xref ref-type="bibr" rid="bibr11-1076029611412362">11</xref>,<xref ref-type="bibr" rid="bibr18-1076029611412362">18</xref></sup> Peak incidence of DVT is between days 2 and 7 post-stroke.<sup><xref ref-type="bibr" rid="bibr40-1076029611412362">40</xref>,<xref ref-type="bibr" rid="bibr41-1076029611412362">41</xref></sup> Deep vein thrombosis most often occurs in the paretic leg though up to 22% will have bilateral DVT.<sup><xref ref-type="bibr" rid="bibr18-1076029611412362">18</xref></sup>
</p>
</sec>
<sec id="section8-1076029611412362">
<title>Risk Factors</title>
<p>Risk factors for VTE in stroke include older age, greater limb weakness,<sup><xref ref-type="bibr" rid="bibr42-1076029611412362">42</xref></sup> greater stroke severity, or severe functional impairment. In one study examining clinically evident and asymptomatic VTE by MRDTI, age &gt;70 (odds ratio [OR] 2.9; 95% confidence interval [CI] 1.1-7.8), and severe functional impairment with Barthel Index ≤90 at 2 days post-event (OR 8.3; 95% CI 2.7-25.2) were associated with a higher risk of VTE. Rates of VTE in the PREVAIL study of patients with National Institute of Health Stroke Scale Scores (NIHSS) of ≥14 were double that of patients with NIHSS &lt;14 (23.1% of 488 using pharmacoprophylaxis vs 11.2% of 1268 patients using pharmacoprophylaxis).<sup><xref ref-type="bibr" rid="bibr18-1076029611412362">18</xref></sup>
</p>
</sec>
</sec>
<sec id="section9-1076029611412362">
<title>Deep Vein Thrombosis Prophylaxis</title>
<p>Both DVT and PE are preventable complications of stroke. Reported rates of VTE after stroke have decreased over the last four decades<sup><xref ref-type="bibr" rid="bibr7-1076029611412362">7</xref></sup>; possibly attributable to parallel improvements in post-stroke care including implementation of stroke units, early mobilization and hydration, and increased early use of antiplatelets. Institution of measures to prevent VTE after stroke is used as a quality indicator for stroke centers.<sup><xref ref-type="bibr" rid="bibr43-1076029611412362">43</xref></sup>
</p>
<p>Additional means of thromboprophylaxis in stroke include mechanical methods (ie, compression stockings) to prevent venous stasis and medical therapy including antiplatelets, heparins, and heparinoids. Risk of VTE must be balanced by potential risk of hemorrhagic complications from pharmacotherapy, particularly in the context of hemorrhagic stroke. Nonpharmacologic methods are commonly used as an adjunct to chemoprophylaxis or in patients with contraindication to anticoagulants.</p>
<p>The literature on evidence-based therapy for both pharmacologic and nonpharmacologic prevention of VTE in stroke is not robust with practice guidelines often being based upon extrapolations from studies in other, primarily surgical, patient groups. The stroke population, however, defies straightforward comparisons to other study populations: they are typically elderly and have more comorbid illness than their counterparts; in addition their duration of immobility may be prolonged and they remain at risk of developing additional complications, such as infection, that may heighten the risk of VTE.</p>
<p>Optimal duration for VTE prophylaxis in stroke patients with prolonged immobility is not well defined. Deep vein thrombosis is reported in the stroke rehabilitation population in up to 10% to 30%; 20% of cases may occur after 12 weeks post-stroke onset.<sup><xref ref-type="bibr" rid="bibr44-1076029611412362">44</xref></sup> Pulmonary embolism may occur up to 4 months post-stroke.<sup><xref ref-type="bibr" rid="bibr39-1076029611412362">39</xref></sup> Some advocate continued prophylaxis for patients with persistent immobility.<sup><xref ref-type="bibr" rid="bibr7-1076029611412362">7</xref>,<xref ref-type="bibr" rid="bibr45-1076029611412362">45</xref></sup> In spinal cord injured patients with complete diplegia, by 6 months post-injury the risk of DVT declines to that of the general population.<sup><xref ref-type="bibr" rid="bibr46-1076029611412362">46</xref></sup> Whether the risk of VTE declines similarly in stroke patients is unknown and requires further study.</p>
</sec>
<sec id="section10-1076029611412362">
<title>Types of DVT Prophylaxis</title>
<sec id="section11-1076029611412362">
<title>Nonpharmacologic</title>
<sec id="section12-1076029611412362">
<title>Early mobilization and hydration</title>
<p>The efficacies of early mobilization and hydration in reducing DVT have not been evaluated directly in clinical trials. Rates of DVT, however, are lower in stroke units encouraging early mobilization.<sup><xref ref-type="bibr" rid="bibr47-1076029611412362">47</xref></sup> Early mobilization is recommended as a means to prevent VTE in guidelines from the America Heart Association/American Stroke Association (AHA/ASA), Canadian Stroke Network (CSN), Australian National Stroke Foundation (NSF), and European Stroke Organization ([ESO] <xref ref-type="table" rid="table3-1076029611412362">Table 3</xref>
). In addition to reducing venous stasis, early mobilization is also associated with reduced depression,<sup><xref ref-type="bibr" rid="bibr54-1076029611412362">54</xref></sup> improved mobility,<sup><xref ref-type="bibr" rid="bibr55-1076029611412362">55</xref></sup> and reduced costs of care.<sup><xref ref-type="bibr" rid="bibr54-1076029611412362">54</xref></sup>
</p>
<table-wrap id="table3-1076029611412362" position="float">
<label>Table 3.</label>
<caption>
<p>Summary of Guidelines by Stroke Type</p>
</caption>
<graphic alternate-form-of="table3-1076029611412362" xlink:href="10.1177_1076029611412362-table3.tif"/>
<table>
<thead>
<tr>
<th align="left">AHA/ASA<sup><xref ref-type="bibr" rid="bibr48-1076029611412362">48</xref></sup>
</th>
<th align="left">Canadian<sup><xref ref-type="bibr" rid="bibr49-1076029611412362">49</xref></sup>
</th>
<th align="left">Australian <sup><xref ref-type="bibr" rid="bibr50-1076029611412362">50</xref></sup>
</th>
<th align="left">ESO<sup><xref ref-type="bibr" rid="bibr51-1076029611412362">51</xref></sup>
</th>
<th align="left">SIGN<sup><xref ref-type="bibr" rid="bibr52-1076029611412362">52</xref></sup>
</th>
<th align="left">ACCP<sup><xref ref-type="bibr" rid="bibr53-1076029611412362">53</xref></sup>
</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left">Ischemic stroke<break/>• Early mobilization (Class I, Level C)<break/>• IPC (Class IIa, Level B)<break/>• ASA is a potential intervention but is less effective than anticoagulants (Class IIa, Level A)<break/>• Subcutaneous anticoagulants recommended for immobilized patients. Timing for initiation unknown. (Class I, Level A)<break/>ICH<break/>• IPC with GCS(Class I, Level B)<break/>• LMWH or UFH may be considered after cessation of bleeding if immobile 1-4 days post-event<break/>(Class IIb, Level B)<break/>SAH<break/>VTE prophylaxis not discussed in 2009 guidelines</td>
<td align="left">All patients<break/>• Patients at high risk<sup><xref ref-type="table-fn" rid="table-fn4-1076029611412362">
a
</xref></sup> should be considered for prophylaxis if no contraindications (Level B)<break/>• Early mobilization and hydration (Level C)<break/>• Optimize secondary prevention measures (including antiplatelets) (Level A)<break/>Ischemic Stroke<break/>• GCS should be considered (Level B)<break/>• Prophylactically dosed LMWH or UFH 5000 IU bid for high-risk patients in absence of contraindications (Level A)ICH/SAH<break/>• GCS should be considered<break/>(Level C)</td>
<td align="left">All patients<break/>• Early mobilization and hydration<break/>(GPP)<break/>• Thigh-length GCS are not recommended (Level B)<break/>Ischemic stroke<break/>• Antiplatelets should be used to help prevent DVT/PE (Level A)<break/>• LMWH or UFH in prophylactic doses can be used with caution for selected patients at high risk. UFH should be used if LMWH is not available (Level B)<break/>ICH/SAH<break/>• Antithrombotic therapy is not recommended (GPP)</td>
<td align="left">Ischemic Stroke<break/>• Early mobilization and hydration (GPP)<break/>• GCS(GPP)<break/>• Low-dose UFH or LMWH should be considered for patients at high risk of VTE (Class I, Level A)</td>
<td align="left">All patients<break/>• No evidence to support/refute mobilization in 48 hours<break/>• Above-knee GCS not recommended (Level A)<break/>Ischemic stroke<break/>• Anticoagulants in the first 2 weeks can cause ICH or hemorrhagic transformation and have no net benefit.<break/>• ASA 300 mg/d should be given to all patients in the first 2 weeks after stroke to prevent VTE if no contraindication (Level A)<break/>• Patients at particularly high risk of early DVT<sup><xref ref-type="table-fn" rid="table-fn5-1076029611412362">b</xref></sup> can be given prophylactic heparin. LMWH recommended over UFH.<break/>• After 2 weeks DVT risk should be reassessed and prophylactic medication (eg, heparin) considered (Level A)</td>
<td align="left">• For medical patients at risk of VTE with contraindication to anticoagulant prophylaxis, GCS, or IPC are recommended (Level 1A)<break/>• Aspirin alone as thromboprophylaxis is not recommended<break/>(Level 1A)<break/>• For acutely ill medical patients admitted with acute neurological disease LMWH (Grade 1A) or low-dose UFH (Grade 1A) are recommended<break/>• For patients undergoing major neurosurgery, routine thromboprophylaxis is recommended (Level 1A) with optimal use of IPC (Level 1A). Postoperative LMWH (Level 2A) or low-dose UFH (Level 2B) are acceptable alternatives to IPC. For patients with particularly high thrombosis risk GCS or IPC can be combined with LMWH or UFH (Grade 2B)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn3-1076029611412362">
<p>Abbreviations: GPP, good practice point; GCS, graduated compression stockings; IPC, intermittent pneumatic compression; LMWH, low-molecular-weight heparin; UFH, unfractionated heparin; ICH, intracerebral hemorrhage; SAH, subarachnoid hemorrhage; DVT, deep vein thrombosis; PE, pulmonary embolism; ASA, American Stroke Association; VTE, venous thromboembolism.</p>
</fn>
<fn id="table-fn4-1076029611412362">
<p>
<sup>a</sup> Defined as including inability to move one or both lower limbs and inability to mobilize independently.</p>
</fn>
<fn id="table-fn5-1076029611412362">
<p>
<sup>b</sup> Hx previous DVT, known thrombophilia, active cancer.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>Dehydration is strongly associated with DVT in stroke.<sup><xref ref-type="bibr" rid="bibr56-1076029611412362">56</xref></sup> Patients with stroke are at particularly high risk of dehydration from reduced fluid intake as a consequence of dysphagia or depressed level of consciousness, even in those who are receiving nasogastric or parental fluids.<sup><xref ref-type="bibr" rid="bibr57-1076029611412362">57</xref></sup> Hydration is recommended for VTE prophylaxis in guidelines from the CSN, NSF, and ESO (<xref ref-type="table" rid="table3-1076029611412362">Table 3</xref>).</p>
</sec>
</sec>
</sec>
<sec id="section14-1076029611412362">
<title>Mechanical Methods to Prevent DVT and PE</title>
<p>Nonpharmacologic methods to prevent VTE are commonly used as an adjunct to chemoprophylaxis or when anticoagulants are contraindicated. Available methods include repetitive electrical stimulation of the calf muscles, graded elastic compression stockings, and intermittent pneumatic compression (IPC) devices. Patients with dermatologic disease, severe peripheral vascular disease, or neuropathy are at greater risk of complications with mechanical therapy.<sup><xref ref-type="bibr" rid="bibr58-1076029611412362">58</xref>,<xref ref-type="bibr" rid="bibr59-1076029611412362">59</xref></sup>
</p>
<sec id="section15-1076029611412362">
<title>Repetitive Electrical Stimulation</title>
<p>Electrical stimulation for the prevention of DVT was first introduced in the medical literature in the 1960s but has not been widely adopted. Induced contraction of calf muscles with intermittent application of low electrical current is thought to increase venous return and thus reduce stasis. Stimulation rates in studies vary from 2 to over 100 pulses per minute. The method has been investigated both as stand alone therapy and as adjunct to anticoagulants in small trials involving surgical<sup><xref ref-type="bibr" rid="bibr60-1076029611412362">60</xref><xref ref-type="bibr" rid="bibr61-1076029611412362"/><xref ref-type="bibr" rid="bibr62-1076029611412362"/>–<xref ref-type="bibr" rid="bibr63-1076029611412362">63</xref></sup> and trauma<sup><xref ref-type="bibr" rid="bibr64-1076029611412362">64</xref>,<xref ref-type="bibr" rid="bibr65-1076029611412362">65</xref></sup> patients, with inconsistent results. Electrical stimulation was investigated in 8 patients with stroke in the pilot phase of a study comparing methods of thromboprophylaxis in rehabilitation, though this method was abandoned due to discomfort and blister formation at electrode sites.<sup><xref ref-type="bibr" rid="bibr66-1076029611412362">66</xref></sup> Studies in healthy controls suggest newer models of electrical stimulation devices employing lower currents may be better tolerated.<sup><xref ref-type="bibr" rid="bibr67-1076029611412362">67</xref>,<xref ref-type="bibr" rid="bibr68-1076029611412362">68</xref></sup> Electrical stimulation remains underexplored in the population with stroke.</p>
</sec>
<sec id="section16-1076029611412362">
<title>Graded Elastic Compression Stockings</title>
<p>Graded elastic compression stockings, commonly known as “TED stockings” in North America, are effective in preventing VTE in surgical patients<sup><xref ref-type="bibr" rid="bibr69-1076029611412362">69</xref></sup> and, prior to CLOTS-1, were recommended for patients with stroke.<sup><xref ref-type="bibr" rid="bibr48-1076029611412362">48</xref>,<xref ref-type="bibr" rid="bibr49-1076029611412362">49</xref>,<xref ref-type="bibr" rid="bibr51-1076029611412362">51</xref></sup>
</p>
<p>The CLOTS-1 trial assessed the efficacy of graded elastic compression stockings in reducing VTE after stroke. A total of 2518 patients unable to ambulate independently within 1 week of ischemic or hemorrhagic stroke (excluding SAH) were randomized to routine care with or without thigh-high graded elastic compression stockings.<sup><xref ref-type="bibr" rid="bibr22-1076029611412362">22</xref></sup> Primary outcome was occurrence of symptomatic or asymptomatic DVT in the popliteal or femoral veins on Doppler US at 7 to 10 days, and, when feasible, 25 to 30 days post-event. In all, 85.2% of participants had ischemic stroke. There was no significant difference between control and intervention groups with respect to the primary outcome, including symptomatic, asymptomatic, and below-knee DVT (10% in the graded elastic compression stockings group, 10.5% control; absolute risk reduction [ARR] 0.5%, 95% CI −1.9%-2.9%) or in PE confirmed by imaging or autopsy. No additional differences emerged in subgroup analyses examining earlier versus later randomization, concomitant use of anticoagulants or thrombolysis, or leg weakness. However, the rate of adverse events with graded elastic compression stockings, including skin necrosis and ulcerations, was 4-fold that of controls (5.1% GCS, 1.3% control; OR 4.18, 95% CI 2.40-7.27).</p>
<p>The CLOTS-2 trial comparing thigh-high versus knee-high graded elastic compression stockings was terminated early in light of results of CLOTS-1. Deep vein thrombosis occurred in 98 (6.3%) patients in the thigh-high group and in 138 (8.8%) in the below-knee group (ARR 2.5%, 95% CI 0.7-4.4; <italic>P</italic> = .008).<sup><xref ref-type="bibr" rid="bibr70-1076029611412362">70</xref></sup> However, given the high adverse event rate, elastic compression stockings cannot be recommended for patients with stroke.</p>
</sec>
<sec id="section17-1076029611412362">
<title>Intermittent Pneumatic Compression Devices</title>
<p>Intermittent pneumatic compression devices are thought to prevent VTE by reducing venous stasis.<sup><xref ref-type="bibr" rid="bibr71-1076029611412362">71</xref></sup> There is some evidence that IPC devices may also affect levels and activity of endogenous fibrinolytic substances, though studies are conflicting.<sup><xref ref-type="bibr" rid="bibr72-1076029611412362">72</xref><xref ref-type="bibr" rid="bibr73-1076029611412362"/><xref ref-type="bibr" rid="bibr74-1076029611412362"/><xref ref-type="bibr" rid="bibr75-1076029611412362"/><xref ref-type="bibr" rid="bibr76-1076029611412362"/>–<xref ref-type="bibr" rid="bibr77-1076029611412362">77</xref></sup> Intermittent pneumatic compression devices are associated with reduced risk of DVT in surgical patients.<sup><xref ref-type="bibr" rid="bibr78-1076029611412362">78</xref></sup>
</p>
<p>Intermittent pneumatic compression devices are recommended after stroke in certain national guidelines (<xref ref-type="table" rid="table3-1076029611412362">Table 3</xref>), though supporting evidence is not robust.<sup><xref ref-type="bibr" rid="bibr48-1076029611412362">48</xref>,<xref ref-type="bibr" rid="bibr49-1076029611412362">49</xref>,<xref ref-type="bibr" rid="bibr53-1076029611412362">53</xref></sup> Four completed studies have investigated IPC devices in stroke. One small study randomized 26 patients within 72 hours of clinically diagnosed stroke to below-knee IPC devices or no IPC devices for 10 days. Patients were evaluated for VTE using <sup>125</sup>I-Fibrinogen scanning daily for 10 days. There was no significant difference between groups in the incidence of DVT (6 of 13 patients in each group).<sup><xref ref-type="bibr" rid="bibr79-1076029611412362">79</xref></sup> Another trial compared thigh-high IPC devices with graded elastic compression stockings versus graded elastic compression stockings alone for 10 ± 2 days in 151 patients with spontaneous or traumatic ICH who were mobile or immobile at randomization. Patients were evaluated at 10 ± 2, 30, and 90 days for DVT using Doppler US. There were fewer DVT in the IPC devices group at day 10 (4.7% IPC devices group vs 15.9% control; relative risk [RR] 0.29, 95% CI 0.08-1.00). All events were asymptomatic. There were 3 proximal DVT in controls and none with IPC devices.<sup><xref ref-type="bibr" rid="bibr25-1076029611412362">25</xref></sup> A meta-analysis of thromboprophylaxis trials<sup><xref ref-type="bibr" rid="bibr80-1076029611412362">80</xref></sup> in an unselected population of neurosurgical patients found that IPC devices were superior to placebo in preventing DVT (RR 0.41, 95% CI 0.21-0.78).</p>
<p>The CLOTS-3 trial is currently investigating routine care with and without IPC devices for prevention of VTE in stroke. The study aims to enroll 2000 participants by 2014 and should provide greater clarity on the efficacy of IPC devices.<sup><xref ref-type="bibr" rid="bibr81-1076029611412362">81</xref></sup>
</p>
</sec>
<sec id="section18-1076029611412362">
<title>Pharmacologic Prophylaxis by Stroke Type</title>
<sec id="section19-1076029611412362">
<title>Ischemic stroke</title>
<p>With pharmacoprophylaxis, clinicians must balance the benefit of VTE risk reduction with associated risk of intracranial and extracranial hemorrhage. Options in ischemic stroke include antiplatelets, unfractionated heparin (UFH), low-molecular-weight heparins (LMWH), factor Xa inhibitors (heparinoids), and direct oral thrombin inhibitors (DTIs).</p>
</sec>
<sec id="section21-1076029611412362">
<title>Antiplatelets</title>
<p>Studies in medical and surgical populations have demonstrated a decreased risk of DVT and PE with antiplatelet use.<sup><xref ref-type="bibr" rid="bibr82-1076029611412362">82</xref>,<xref ref-type="bibr" rid="bibr83-1076029611412362">83</xref></sup> The mainstay of secondary prevention in noncardioembolic stroke, antiplatelets are also associated with a modest decrease in VTE in some stroke trials. Patients in The International Stroke Trial (IST)<sup><xref ref-type="bibr" rid="bibr84-1076029611412362">84</xref></sup> receiving 300 mg of aspirin (ASA) daily had lower rates of PE than patients in the non-ASA group (0.7% of 4858 ASA patients, 0.9% of 4859 controls; OR 0.80, 95% CI 0.51-1.24). There was no difference in rates of PE in stroke patients given 160 mg ASA daily versus placebo in the Chinese Acute Stroke Trial (0.1% of 10 335 ASA patients, 0.2% of 10 320 control). Neither study prospectively evaluated VTE or had predetermined criteria for PE.<sup><xref ref-type="bibr" rid="bibr30-1076029611412362">30</xref></sup> A meta-analysis acknowledges that PE may have been underreported.<sup><xref ref-type="bibr" rid="bibr15-1076029611412362">15</xref></sup> A Cochrane review found a significantly lower rate of PE with antiplatelets as compared to control (71 of 20 664 antiplatelet patients vs 100 of 20 661 controls; OR 0.71, 95% CI 0.53-0.96). Deep vein thrombosis rates were only provided in 2 small studies with significant heterogeneity; there was a nonsignificant reduction with antiplatelets as compared to control (23.9% of 67 antiplatelet participants vs 28.8% of 66 controls; OR 0.78, 95% CI 0.36-1.67; <italic>P</italic> = .52).<sup><xref ref-type="bibr" rid="bibr85-1076029611412362">85</xref></sup> The American College of Chest Physicians (ACCP) does not recommend aspirin monotherapy for thromboprophylaxis after stroke; Canadian guidelines recommend that antiplatelets use be optimized for secondary stroke prevention (<xref ref-type="table" rid="table3-1076029611412362">Table 3</xref>), but in both cases any reduction in VTE is a secondary benefit of strategies to prevent recurrent arterial stroke.<sup><xref ref-type="bibr" rid="bibr49-1076029611412362">49</xref>,<xref ref-type="bibr" rid="bibr53-1076029611412362">53</xref></sup>
</p>
</sec>
<sec id="section22-1076029611412362">
<title>Heparins and heparinoids</title>
<p>In comparison to placebo, low-to-medium dose UFH, LMWH, and heparinoids have all been shown to reduce VTE after stroke.<sup><xref ref-type="bibr" rid="bibr93-1076029611412362">93</xref></sup> Which one method is most efficacious is controversial. Direct comparison of low-dose (5000 IU twice daily [bid]) versus medium-dose (thrice daily [tid]) UFH has not been investigated, though in the International Stroke Trial, 10 000 IU daily did not reduce PE over placebo (<xref ref-type="table" rid="table4-1076029611412362">Table 4</xref>
).<sup><xref ref-type="bibr" rid="bibr84-1076029611412362">84</xref></sup> Unlike UFH, LMWH has a longer half-life and can be dosed daily without monitoring, has more predictable pharmacokinetics, and a lower risk of heparin-induced thrombocytopenia (HIT). Low-molecular-weight heparin is not well reversed with protamine sulfate in the event of bleeding and is renally cleared, requiring cautious dosing in patients with renal failure. Heparinoids more selectively inhibit factor Xa and carry very low risk of HIT but cannot be reversed. Unfractionated heparin is the least expensive and can be reversed with protamine if bleeding occurs.<sup><xref ref-type="bibr" rid="bibr94-1076029611412362">94</xref></sup> Anticoagulation should be avoided in the first 24 hours postthrombolysis; whether anticoagulation can be safely initiated before the first 24 hours in nonthrombolysis patients has not been studied.<sup><xref ref-type="bibr" rid="bibr7-1076029611412362">7</xref>,<xref ref-type="bibr" rid="bibr95-1076029611412362">95</xref>,<xref ref-type="bibr" rid="bibr88-1076029611412362">88</xref></sup>
</p>
<table-wrap id="table4-1076029611412362" position="float">
<label>Table 4.</label>
<caption>
<p>Commonly Used Antithrombotic Medications for DVT Prophylaxis in Ischemic Stroke and Relevant Trials<sup><xref ref-type="table-fn" rid="table-fn7-1076029611412362">a</xref></sup>
</p>
</caption>
<graphic alternate-form-of="table4-1076029611412362" xlink:href="10.1177_1076029611412362-table4.tif"/>
<graphic alternate-form-of="table4-1076029611412362" xlink:href="10.1177_1076029611412362-table4a.tif"/>
<table>
<thead>
<tr>
<th>Trial</th>
<th>Year</th>
<th>Comparison</th>
<th>N</th>
<th>Thrombotic Events</th>
<th>Screening Modality for Asymptomatic Disease</th>
<th>Symptomatic Intracranial Hemorrhage</th>
<th>Time to Initiation of Treatment</th>
<th>Duration of Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="9">UFH vs placebo</td>
</tr>
<tr>
<td rowspan="2"> McCarthy<sup><xref ref-type="bibr" rid="bibr10-1076029611412362">10</xref></sup>*</td>
<td rowspan="2">1986</td>
<td rowspan="2">5000 IU tid</td>
<td rowspan="2">305</td>
<td>DVT 22% vs 73%, <italic>P</italic> &lt; .001</td>
<td rowspan="2">DVT: Daily <sup>125</sup>I fibrinogen scanning</td>
<td rowspan="2">5.6% vs 4.2%, <italic>P</italic> = NS</td>
<td rowspan="2">Within 48 hours</td>
<td rowspan="2">14 days</td>
</tr>
<tr>
<td>PE 9.9 vs 46%, <italic>P</italic> &lt; .01</td>
</tr>
<tr>
<td rowspan="2"> Pambianco<sup><xref ref-type="bibr" rid="bibr67-1076029611412362">67</xref></sup>
</td>
<td rowspan="2">1995</td>
<td rowspan="2">5000 IU tid</td>
<td rowspan="2">135</td>
<td>DVT 4.2% vs 5.2%</td>
<td rowspan="2">DVT: Twice weekly Doppler US</td>
<td rowspan="2">0% vs 0%, <italic>P</italic> = NS</td>
<td rowspan="2">Mean 24 days</td>
<td rowspan="2">28 days</td>
</tr>
<tr>
<td>N/A</td>
</tr>
<tr>
<td rowspan="2"> IST<sup><xref ref-type="bibr" rid="bibr15-1076029611412362">15</xref></sup>
</td>
<td rowspan="2">1997</td>
<td rowspan="2">5000 IU or 12500 IU bid</td>
<td rowspan="2">9712</td>
<td>DVT N/A</td>
<td rowspan="2">N/A</td>
<td rowspan="2">1.2 vs 0.3%<italic>P</italic> &lt; .00001</td>
<td rowspan="2">Within 48 hours of stroke</td>
<td rowspan="2">14 days</td>
</tr>
<tr>
<td>PE 0.7% vs 0.9%<italic>P</italic> = .14</td>
</tr>
<tr>
<td colspan="9">LMWH vs Placebo</td>
</tr>
<tr>
<td rowspan="2"> Sandset<sup><xref ref-type="bibr" rid="bibr13-1076029611412362">13</xref></sup>
</td>
<td rowspan="2">1990</td>
<td rowspan="2">Dalteparin 3000-5500 IU qd</td>
<td rowspan="2">103</td>
<td>DVT 36% v. 34%, <italic>P</italic> = NS</td>
<td rowspan="2">DVT: Unilateral venography of paretic limb</td>
<td rowspan="2">3.8%% vs 2.0%, <italic>P</italic> = NS</td>
<td rowspan="2">Within 72 hours of stroke</td>
<td rowspan="2">14 days</td>
</tr>
<tr>
<td>PE 4% vs 4%, <italic>P</italic> = NS</td>
</tr>
<tr>
<td rowspan="2"> Prins<sup><xref ref-type="bibr" rid="bibr12-1076029611412362">12</xref></sup>
</td>
<td rowspan="2">1989</td>
<td rowspan="2">Dalteparin 2500 IU bid</td>
<td rowspan="2">60</td>
<td>DVT 20% vs 50%, <italic>P</italic> = .05</td>
<td rowspan="2">DVT: Daily <sup>125</sup>I fibrinogen scanning followed by venography if positive</td>
<td rowspan="2">3.3% vs 0%, <italic>P</italic> = NS</td>
<td rowspan="2">Within 72 hours of stroke</td>
<td rowspan="2">14 days</td>
</tr>
<tr>
<td>PE 3.3% vs 6.6%,<italic>P</italic> = NS</td>
</tr>
<tr>
<td rowspan="2"> Kay<sup><xref ref-type="bibr" rid="bibr14-1076029611412362">14</xref></sup>
</td>
<td rowspan="2">1995</td>
<td rowspan="2">Nadroparin 4100 IU qd or bid</td>
<td rowspan="2">312</td>
<td>DVT 0% vs 1%, <italic>P</italic> = NS</td>
<td rowspan="2">N/A</td>
<td rowspan="2">0% vs 1%, <italic>P</italic> = NS</td>
<td rowspan="2">Within 48 hours of stroke</td>
<td rowspan="2">10 days</td>
</tr>
<tr>
<td>PE 0% vs 0%, <italic>P</italic> = NS</td>
</tr>
<tr>
<td colspan="9">Heparinoid vs Placebo</td>
</tr>
<tr>
<td rowspan="2"> Turpie<sup><xref ref-type="bibr" rid="bibr11-1076029611412362">11</xref></sup>
</td>
<td rowspan="2">1987</td>
<td rowspan="2">Danaparoid 750 IU bid</td>
<td rowspan="2">75</td>
<td>DVT 4% vs 28%, <italic>P</italic> = .005</td>
<td rowspan="2">DVT: Regular <sup>125</sup>I fibrinogen scanning and impedance plethysmography followed by venography if positive</td>
<td rowspan="2">2.0% vs 0%, <italic>P</italic> = NS</td>
<td rowspan="2">Within 7 days of stroke</td>
<td rowspan="2">30 days</td>
</tr>
<tr>
<td>PE 0% vs 8%, <italic>P</italic> = NS</td>
</tr>
<tr>
<td rowspan="2"> TOAST<sup><xref ref-type="bibr" rid="bibr16-1076029611412362">16</xref></sup>
</td>
<td rowspan="2">1998</td>
<td rowspan="2">Danaparoid continuous IV to keep anti-Xa between 0.6-0.8 U/mL</td>
<td rowspan="2">1281</td>
<td>DVT 0.3% vs 1.6%, <italic>P</italic> &lt; .05</td>
<td rowspan="2">N/A</td>
<td rowspan="2">2.2% vs 1.1%, <italic>P</italic> = 0.13</td>
<td rowspan="2">Within 24 hours of stroke</td>
<td rowspan="2">7 days</td>
</tr>
<tr>
<td>PE 0.3% vs 0.6%<italic>P</italic> = NS</td>
</tr>
<tr>
<td colspan="9">Heparin/heparinoid vs ASA</td>
</tr>
<tr>
<td> HAESTE<sup><xref ref-type="bibr" rid="bibr86-1076029611412362">86</xref></sup>
</td>
<td>2002</td>
<td>Dalteparin 100 IU/kg bid vs, ASA 160 mg qd</td>
<td>449</td>
<td>DVT and PE 0.4% vs 2.2%, <italic>P</italic> = NS, OR 0.2, 95% CI 0.02-1.7</td>
<td>N/A</td>
<td>2.7% vs 1.8%, <italic>P</italic> = NS OR 1.52, 95% CI 0.42-5.46</td>
<td>Started within 30 hours of stroke</td>
<td>14 days</td>
</tr>
<tr>
<td rowspan="2"> TAIST<sup><xref ref-type="bibr" rid="bibr87-1076029611412362">87</xref></sup>
</td>
<td rowspan="2">2001</td>
<td rowspan="2">Tinzaparin 175 IU/kg qd vs, ASA 300 mg qd</td>
<td rowspan="2">732</td>
<td>DVT 0 vs 1.8%, <italic>P</italic> = NS, OR 0, 95% CI 0-9.3</td>
<td rowspan="2">N/A</td>
<td rowspan="2">1.4% vs 0.2%, <italic>P</italic> &lt; 0.05, OR 7.15, 95% CI 1.1-163</td>
<td rowspan="2">Within 48 hours of stroke</td>
<td rowspan="2">Up to 10 days</td>
</tr>
<tr>
<td>PE 0.4% vs 0.8%, <italic>P</italic> = NS, OR 0.5, 95% CI 0.06-2.85</td>
</tr>
<tr>
<td rowspan="2"> TAIST<sup><xref ref-type="bibr" rid="bibr87-1076029611412362">87</xref></sup>
</td>
<td rowspan="2">2001</td>
<td rowspan="2">Tinzaparin 100 IU/kg qd vs, ASA 300 mg qd</td>
<td rowspan="2">752</td>
<td>DVT 0.6% vs 1.8%, <italic>P</italic> = NS, OR 0.32, 95% CI 0.02-1.14</td>
<td rowspan="2">N/A</td>
<td rowspan="2">0.6% vs 0.2%, <italic>P</italic> = NS, OR 2.91, 95% CI 0.31-77</td>
<td rowspan="2">Within 48 hours of stroke</td>
<td rowspan="2">Up to 10 days</td>
</tr>
<tr>
<td>PE 0.8% vs 0.8%<italic>P</italic> = NS, OR 0.97, 95% CI 0.22-4.31</td>
</tr>
<tr>
<td rowspan="2"> IST<sup><xref ref-type="bibr" rid="bibr15-1076029611412362">15</xref></sup>
</td>
<td rowspan="2">1997</td>
<td rowspan="2">UFH 12500 IU bid vs ASA 300 mg qd</td>
<td rowspan="2">4855</td>
<td>N/A</td>
<td rowspan="2">N/A</td>
<td rowspan="2">1.8% vs 0.5%, <italic>P</italic> &lt; .001</td>
<td rowspan="2">Within 48 hours of stroke</td>
<td rowspan="2">Up to 14 days</td>
</tr>
<tr>
<td>PE 0.5% vs 0.7%<italic>P</italic> = NS</td>
</tr>
<tr>
<td rowspan="2"> IST<sup><xref ref-type="bibr" rid="bibr15-1076029611412362">15</xref></sup>
</td>
<td rowspan="2">1997</td>
<td rowspan="2">UFH 5000 IU bid vs ASA 300 mg qd</td>
<td rowspan="2">4858</td>
<td>N/A</td>
<td rowspan="2">N/A</td>
<td rowspan="2">0.7% vs 0.5%, <italic>P</italic> = NS</td>
<td rowspan="2">Within 48 hours of stroke</td>
<td rowspan="2">Up to 14 days</td>
</tr>
<tr>
<td>PE 0.8% vs 0.7%, <italic>P</italic> = NS</td>
</tr>
<tr>
<td colspan="9">LMWH vs UFH</td>
</tr>
<tr>
<td rowspan="2"> PREVAIL<sup><xref ref-type="bibr" rid="bibr88-1076029611412362">88</xref></sup>
</td>
<td rowspan="2">2007</td>
<td rowspan="2">Enoxaparin 40 mg qd vs, UFH 5000 IU bid</td>
<td rowspan="2">1335</td>
<td>DVT 10% vs 18%, <italic>P</italic> = .0001, RR 0.57, 95% CI 0.44-0.76</td>
<td rowspan="2">DVT: Bilateral contrast venography at end of study period</td>
<td rowspan="2">1% vs 0.1%, <italic>P</italic> = NS RR 0.66, 95% CI 0.19-2.34</td>
<td rowspan="2">Within 48 hours of stroke</td>
<td rowspan="2">6-14 days</td>
</tr>
<tr>
<td>PE 0.2% vs 1%, <italic>P</italic> = .06, RR 0.17, 95% CI 0.02-1.39</td>
</tr>
<tr>
<td rowspan="2"> PROTECT<sup><xref ref-type="bibr" rid="bibr89-1076029611412362">89</xref></sup>
</td>
<td rowspan="2">2006</td>
<td rowspan="2">Certoparin 3000 U qd vs, UFH 5000 IU tid</td>
<td rowspan="2">545</td>
<td>DVT 6.6% vs 8.4%</td>
<td rowspan="2">DVT: Regular Doppler US, ICH: CT at onset and days 7-8</td>
<td rowspan="2">0.7% vs 1.0%</td>
<td rowspan="2">Within 24 hours of stroke</td>
<td rowspan="2">12-16 days</td>
</tr>
<tr>
<td>PE 0% vs 0%</td>
</tr>
<tr>
<td rowspan="2"> Hillbom<sup><xref ref-type="bibr" rid="bibr90-1076029611412362">90</xref></sup>
</td>
<td rowspan="2">2002</td>
<td rowspan="2">Enoxaparin 40 mg qd vs, UFH 5000 IU tid</td>
<td rowspan="2">212</td>
<td>DVT 16% vs 24.5%</td>
<td rowspan="2">DVT: bilateral ascending phlebography at days 8-12, ICH: CT at days 8-12</td>
<td rowspan="2">0.9% vs 0%</td>
<td rowspan="2">Within 48 hours of stroke</td>
<td rowspan="2">8-12 days</td>
</tr>
<tr>
<td>PE 1.9% vs 3.8%</td>
</tr>
<tr>
<td colspan="9">Heparinoid vs UFH</td>
</tr>
<tr>
<td rowspan="2"> Dumas<sup><xref ref-type="bibr" rid="bibr91-1076029611412362">91</xref></sup>
</td>
<td rowspan="2">1994</td>
<td rowspan="2">Danaparoid 1250 IU qd vs, UFH 5000 IU bid</td>
<td rowspan="2">179</td>
<td>DVT 14% vs 19%<italic>P</italic> = NS</td>
<td rowspan="2">DVT: Daily <sup>125</sup>I fibrinogen scanning followed by venography if positive ICH: CT at start and end of study period</td>
<td rowspan="2">4.5% vs 4.5%<italic>P</italic> = NS</td>
<td rowspan="2">Within 48 hours of stroke</td>
<td rowspan="2">9-13 days</td>
</tr>
<tr>
<td>PE 4.5% vs 4.5% <italic>P</italic> = NS</td>
</tr>
<tr>
<td rowspan="2"> Turpie<sup><xref ref-type="bibr" rid="bibr92-1076029611412362">92</xref></sup>
</td>
<td rowspan="2">1992</td>
<td rowspan="2">Danaparoid 750 IU bid vs, UFH 5000 IU bid</td>
<td rowspan="2">87</td>
<td>DVT 9% vs 31%, <italic>P</italic> &lt; .01, RR 0.71, 95% CI 0.16-0.93</td>
<td rowspan="2">DVT: Daily <sup>125</sup>I fibrinogen scanning followed by venography if positive, ICH: CT at day 14</td>
<td rowspan="2">0% vs 0%</td>
<td rowspan="2">1-20 days post-stroke (Mean 6 days)</td>
<td rowspan="2">14 days</td>
</tr>
<tr>
<td>N/A</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn6-1076029611412362">
<p>Abbreviations: UFH, unfractionated heparin; ICH, intracerebral hemorrhage; CT, computed tomography; DVT, deep vein thrombosis; PE, pulmonary embolism; ASA, American Stroke Association; N/A, not available; NS, not significant; bid, twice daily; tid, thrice daily; qd, every day.</p>
</fn>
<fn id="table-fn7-1076029611412362">
<p>
<sup>a</sup> Heparin/heparinoid vs ASA.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>A recent Cochrane review found that danaparoid and LMWH were both associated with significant reduction in DVT over UFH (OR 0.55, 95% CI 0.44-0.70; <italic>P</italic> &lt; .00001); though this difference was no longer significant (OR 0.86, 95% CI 0.70-1.06) when analyzed in a “modified worst-case scenario” where patients who were not systematically screened for DVT and were assumed to have an event rate equivalent to that of the highest rate in controls out of all available trials (31%). Rates of PE, and intracranial and extracranial hemorrhages were too small to provide a reliable comparison between treatments.<sup><xref ref-type="bibr" rid="bibr87-1076029611412362">87</xref></sup>
</p>
</sec>
<sec id="section23-1076029611412362">
<title>Unfractionated heparin versus LMWH</title>
<p>In the pre-thrombolysis era, 212 patients were randomized within 48 hours of noncardioembolic ischemic stroke to 10 ± 2 days of enoxaparin 40 mg daily or UFH 5000 IU tid. There was no significant difference in the rates of DVT (16% LMWH vs 24.5% UFH), PE (1.9% vs 3.8%), intracranial hemorrhage (0.9% vs 0%), hemorrhagic transformation (13.2% vs 18.9%), or mortality (19.8% vs 26.4%). There was a trend toward increased bleeding with LMWH as compared with UFH (2.8% vs 1.9%).<sup><xref ref-type="bibr" rid="bibr96-1076029611412362">96</xref></sup>
</p>
<p>The PROTECT trial, powered for noninferiority, randomized 545 nonthrombolysis ischemic stroke patients to LMWH cetroparin 3000 U daily or UFH 5000 IU tid. There was no significant difference in the primary end points of proximal DVT, PE, or VTE-associated death (6.6% LMWH vs 8.8% UFH, 97.5% CI −100.0-2.3; <italic>P =</italic> .008 with limit of noninferiority of 5% and <italic>P</italic> = .0117 with limit of 3%), and no difference in major intra- or extracranial bleeding (1.8% UFH vs 1.1% LMWH) or mortality (2.7% in each group).<sup><xref ref-type="bibr" rid="bibr90-1076029611412362">90</xref></sup>
</p>
<p>The PREVAIL trial compared enoxaparin 40 mg daily to UFH 5000 IU bid within 48 hours after ictus for 10 ± 4 days after ischemic stroke in 1762 patients. Thrombolysis was an exclusion criterion only if it occurred less than 24 hours prior to randomization. Primary outcomes were symptomatic or asymptomatic DVT and symptomatic or fatal PE. Symptomatic intracranial or major extracranial hemorrhage and all-cause mortality were primary safety end points. Contrast venography, or Doppler US if venography could not be performed, occurred at day 10 ± 4. In all, 6% of the enoxaparin group and 7% of the UFH group received thrombolysis; 92% of the enoxaparin group and 90% of the UFH group took concomitant antiplatelets. There was significantly less DVT with enoxaparin (10% vs 17%, RR 0.57; 95% CI 0.43-0.75, <italic>P</italic> &lt; .0001) and fewer PE though this did not reach significance due to a low event rate (&lt;1% vs 1%, RR 0.17; 95% CI 0.02-1.39, <italic>P</italic> &lt; .059). There was no difference in the rates of symptomatic intracranial hemorrhage (1% in each group, RR 0.66; 95% CI 0.19-2.34, <italic>P</italic> = .55), though the rates of major extracranial hemorrhage were significantly higher with enoxaparin (1% enoxaparin vs 0% UFH, <italic>P</italic> = .015). All-cause mortality at 14 and 90 days did not differ between groups. Thromboembolic events were 2-fold higher with NIHSS &lt; 14 than with NIHSS ≥ 14 (8.3% enoxaparin and 14.0% UFH with NIHSS &lt;14; 16.3% and 29.7% with NIHSS ≥ 14) though there was still significant benefit with enoxaparin. Bleeding events were also 2-fold higher in patients with more severe strokes (8.1% and 13.6% with NIHSS &lt;14% and 16.3% and 29.1% with NIHSS ≥ 14), though there were no differences in bleeding rates with either drug. There was no significant benefit in favor of UFH in patients over the age of 75 in subgroup analysis (OR 0.72; 95% CI 0.41-1.28).<sup><xref ref-type="bibr" rid="bibr95-1076029611412362">95</xref></sup> Critics of the study have drawn attention to the fact that enoxaparin was compared to a lower dose of heparin than in previous trials<sup><xref ref-type="bibr" rid="bibr89-1076029611412362">89</xref>,<xref ref-type="bibr" rid="bibr97-1076029611412362">97</xref></sup> comparing the 2, that the trial was underpowered to detect hemorrhages, and that the study population was not representative of a typical stroke population given that three quarters of participants were under the age of 75.</p>
</sec>
<sec id="section24-1076029611412362">
<title>Unfractionated heparin versus heparinoids</title>
<p>Danaparoid is the only Xa inhibitor investigated for VTE prophylaxis in stroke and has been compared against UFH in 2 trials in the pre-thrombolysis era. One study randomized 179 patients with ischemic stroke and leg weakness within 72 hours of onset to danaparoid 1250 IU daily or UFH 5000 IU bid for a minimum of 9 days. Patients underwent daily <sup>125</sup>I-fibrogen scanning for DVT. There was no significant difference in the rates of DVT (14.6% danaparoid and 19.8% UFH, <italic>P</italic> = .392), PE (1.1% in each), symptomatic intracranial hemorrhage (1.1% in each), or all-cause mortality at 3 months. There was 1 major extracranial bleed with danaparoid and none with UFH.<sup><xref ref-type="bibr" rid="bibr98-1076029611412362">98</xref></sup>
</p>
<p>Another study compared danaparoid 750 IU bid to UFH 5000 IU bid in 87 patients with ischemic stroke and leg weakness. Treatment was started as soon as possible and continued for 14 days or until discharge. The study ended prematurely due to stalled recruitment. There was a reduction in all DVT (8.9% danaparoid vs 31.0% UFH, relative risk reduction [RRR] 0.71; 95% CI 0.16-0.93, <italic>P</italic> = .014) but not in proximal DVT alone (11.9% vs 4.4%, RRR 0.63; 95% CI −1.14-0.96, <italic>P</italic> &gt; .2). There was no symptomatic intracranial hemorrhage in either group. There was 1 major hemorrhage with danaparoid and none with UFH.<sup><xref ref-type="bibr" rid="bibr91-1076029611412362">91</xref></sup>
</p>
</sec>
<sec id="section25-1076029611412362">
<title>Direct oral thrombin inhibitors</title>
<p>There are no trials to date examining DTIs for the prevention of VTE after stroke. Direct thrombin inhibitor inactivates fibrin-bound thrombin and carries no risk of HIT but is associated with gastrointestinal discomfort. Dabigatran has been compared with enoxaparin for VTE prophylaxis after hip and knee arthroplasty. A recent Cochrane review found that DTIs, including dabigatran, are not superior to LMWH for prevention of VTE in orthopedic surgery, and that a detailed evaluation of symptomatic VTE events and mortality as well as more robust follow-up are required to more fully determine the safety profile of dabigatran.<sup><xref ref-type="bibr" rid="bibr92-1076029611412362">92</xref></sup>
</p>
</sec>
</sec>
</sec>
<sec id="section26-1076029611412362">
<title>Intracerebral Hemorrhage</title>
<p>The risk of facilitating hematoma expansion or causing another intracranial bleed in a patient with underlying susceptibility dissuades many clinicians from using anticoagulants for VTE prophylaxis in ICH. There is inconsistency among guidelines for VTE prophylaxis in ICH (<xref ref-type="table" rid="table3-1076029611412362">Table 3</xref>).<sup><xref ref-type="bibr" rid="bibr53-1076029611412362">53</xref></sup> A recent study<sup><xref ref-type="bibr" rid="bibr99-1076029611412362">99</xref></sup> of the American “Get With the Guidelines—Stroke” registry found patients with ICH are also less likely to receive DVT prophylaxis per AHA/ASA guidelines than patients with ischemic stroke (OR 0.65; 95% CI 0.59-0.71).</p>
<p>The few studies published on anticoagulants for thromboprophylaxis in ICH suggest that they may be well tolerated, though this possibly reflects publication bias. Most hematoma expansion occurs early in ICH,<sup><xref ref-type="bibr" rid="bibr100-1076029611412362">100</xref></sup> and the limited available data suggest that anticoagulation initiated 48 hours after the ictus may be safe, though this will need to be explored with large prospective randomized trials.</p>
<sec id="section27-1076029611412362">
<title>Unfractionated heparin</title>
<p>One trial investigated UFH 5000 U tid in 68 patients with ICH. Patients were designated to begin therapy on the second (22 patients), fourth<sup><xref ref-type="bibr" rid="bibr32-1076029611412362">32</xref></sup>, or tenth<sup><xref ref-type="bibr" rid="bibr32-1076029611412362">32</xref></sup> day following admission. The day 2 group had a significant reduction in PE that was clinically evident or detected by ventilation-perfusion scan (1 patient vs 5 in the day 4 group and 9 in the day 10 group). There was no rebleeding in the day 2 group. The timing of the rebleeding in the day 4 (1 patient) and day 10 (3 patients) groups was not described.<sup><xref ref-type="bibr" rid="bibr41-1076029611412362">41</xref>,<xref ref-type="bibr" rid="bibr101-1076029611412362">101</xref></sup>
</p>
</sec>
<sec id="section29-1076029611412362">
<title>Low-molecular-weight heparin</title>
<p>A total of 75 patients with ICH were randomized after 48 hours postadmission to enoxaparin 40 mg daily plus thigh-high GCS or GCS alone in 1 trial. There was no evidence in either group of hematoma expansion on computed tomography (CT) at 72 hours or later. At 1 week, there was no significant difference in DVT on Doppler US (3 in LMWH group, 1 in control; <italic>P</italic> = 1.0) or PE on spiral CT (1 patient in each group). There were no bleeding complications in either group.<sup><xref ref-type="bibr" rid="bibr102-1076029611412362">102</xref></sup>
</p>
<p>One study examined a retrospective cohort of 407 patients with ICH who survived &gt;48 hours after symptom onset admitted to a tertiary care center from 1993 to 2004. The exact criteria for initiating anticoagulation was not clearly outlined but appeared to be at the discretion of the treating physician, and use of anticoagulants for thromboprophylaxis appeared to increase in popularity during the study period. A total of 232 patients received anticoagulation—202 were given 20 mg enoxaparin daily, 24 received 40 mg, and 6 received other types of LMWH; 175 received neither pharmacological nor mechanical prophylaxis. Anticoagulation was initiated after 24 hours in 23%, after 48 hours in 61%, and after more than 120 hours in 16%. There was no significant difference in the rates of PE (2%, standard deviation [SD] 1 in each group), hematoma expansion (11.9%, SD 16.5 in LMWH; 11.5%, SD 11.1 control), GI bleeding, or other thromboembolic complications (6% SD 3 in LMWH; 4% SD 2 in control).<sup><xref ref-type="bibr" rid="bibr103-1076029611412362">103</xref></sup>
</p>
<p>Safety of thromboprophylaxis in ICH has been evaluated in 2 retrospective cohorts of neurocritical care patients receiving either LMWH or UFH. One study<sup><xref ref-type="bibr" rid="bibr104-1076029611412362">104</xref></sup> with 97 patients initiated therapy after 36 hours without evidence of hematoma expansion on repeat CT; 2 patients experienced hematoma expansion of 20.9% and 22.4%, 1 being symptomatic on day 7 and the other having asymptomatic change discovered on neuroimaging at day 9. The other study evaluated 73 patients who had ICH with intraventricular extension. Antithrombotic therapy was initiated 7 days after ictus; 2 experienced hematoma volume growth &gt;33% within 4 days of thromboprophylaxis.<sup><xref ref-type="bibr" rid="bibr105-1076029611412362">105</xref></sup>
</p>
<p>The safety and efficacy profile of anticoagulation in comparison to mechanical methods is not well defined and the literature would benefit from large randomized trials. The available studies are small and their methodology is not ideal. Their reported rates of VTE are far lower than those from more rigorous trials assessing the rates of VTE in stroke. Still, the current available data suggest that anticoagulants for VTE prophylaxis may be well tolerated in ICH.</p>
</sec>
</sec>
<sec id="section30-1076029611412362">
<title>Subarachnoid Hemorrhage</title>
<p>Retrospective series in SAH patients given low-dose UFH and LMWH suggest that there is a low rate of iatrogenic intracranial hemorrhage but this would need to be confirmed in the context of large randomized trials with rigorous definition of VTE. A recent meta-analysis of 30 studies on VTE prophylaxis in neurosurgical patients found those undergoing surgery for “vascular procedures” had higher rates of intracranial hemorrhage.<sup><xref ref-type="bibr" rid="bibr80-1076029611412362">80</xref></sup>
</p>
<p>A study conducted on patients with aneurysmal SAH between 1978 and 1980 found a 14% incidence of symptomatic DVT confirmed by contrast venography. Patients did not receive antifibrinolytics and were mobilized on the second postoperative day. Not surprisingly there was a lower rate of DVT in those patients operated on within the first week after ictus than in those who underwent surgery 2 to 3 weeks post-SAH (10% vs 17%). No patients experienced clinical PE. The timing of DVT in relation to surgery was not explained. Patients with DVT underwent immediate anticoagulation with 5 days of heparin and 3 months of warfarin. There were no bleeding complications in any patients receiving anticoagulation, though the duration of follow-up was not reported.<sup><xref ref-type="bibr" rid="bibr33-1076029611412362">33</xref></sup>
</p>
<p>In a retrospective cohort of 250 patients with aneurysmal SAH who received endovascular or surgical treatment and survived &gt;15 days, all received pre- and postoperative UFH 5000 bid, GCS, and IPC. In all, 18% developed symptomatic DVT and 2% developed symptomatic PE confirmed by spiral CT. A subgroup of 125 patients who received regular screening with Doppler US had a 24% rate of DVT. On multivariate analysis, DVT was associated with number of days in hospital and number of days in ICU. The authors mention that there were “no major ICH directly linked to the use of UFH” but do not elaborate as to whether there were other ICH under other circumstances.<sup><xref ref-type="bibr" rid="bibr106-1076029611412362">106</xref></sup>
</p>
<p>In another retrospective study, a cohort of 235 aneurysmal SAH patients received UFH 5000 bid (73% of patients) or enoxaparin 40 mg od (25%), depending on physician preference. A small proportion (4%) received a combination of both. The authors did not state whether prophylaxis was started pre- or postoperatively. A subset of 178 patients were screened by Doppler US for DVT before or at day 12 ± 2. Prevalence of DVT was 3.4% in the screened group and 0% in the clinical group. Incidence of PE confirmed by V/Q scan or spiral CT was 1.1% in the screened group and 0% in the clinical group. There was a 1.3% incidence of new intracranial hemorrhage on follow-up imaging, though the authors did not clarify which patient group experienced hemorrhage, whether the hemorrhage was symptomatic, or when the reimaging occurred.<sup><xref ref-type="bibr" rid="bibr32-1076029611412362">32</xref></sup>
</p>
<p>In a randomized, double-blind study investigating the effects of LMWH on preventing delayed ischemia in SAH due to vasospasm, 170 aneurysmal SAH patients receiving routine care with nimodipine and triple-H therapy (hypervolemia, hypertension, and hemodilution)<sup><xref ref-type="bibr" rid="bibr107-1076029611412362">107</xref></sup> were given enoxaparin 40 mg daily or placebo. The study drug was initiated within 72 hours after ictus and within 12 to 24 hours after the aneurysm had been secured through surgical or endovascular means. There was a significantly lower rate of associated intraparenchymal hemorrhage in the enoxaparin group at randomization. There was no significant difference between groups with respect to reversible or fixed delayed ischemia. There were 4 cases of postoperative bleeding with enoxaparin and none with placebo. There were more symptomatic DVT and PE with placebo (3 and 1 in the placebo group, respectively; 1 and 0 in the enoxaparin group). The authors concluded against routine use of enoxaparin in the early postoperative period in SAH.<sup><xref ref-type="bibr" rid="bibr34-1076029611412362">34</xref></sup>
</p>
<p>Some centers use anticoagulation routinely in patients with SAH.<sup><xref ref-type="bibr" rid="bibr32-1076029611412362">32</xref>,<xref ref-type="bibr" rid="bibr106-1076029611412362">106</xref></sup> The evidence for efficacy of anticoagulation in patients with SAH for VTE prophylaxis in comparison to mechanical methods is not well defined nor is the rate of ICH in SAH patients receiving anticoagulation. The risks and benefits of routine anticoagulation in this patient population would be better defined with the aid of rigorous clinical trials.</p>
</sec>
<sec id="section31-1076029611412362">
<title>Guidelines</title>
<p>The controversy surrounding thromboprophylaxis in stroke is illustrated by differences among several national guidelines on post-stroke care (<xref ref-type="table" rid="table3-1076029611412362">Table 3</xref>). Early mobilization and hydration are advocated by the majority. Most of the guidelines were published prior to the release of the results of the CLOTS-1 trial; those published afterward recommend against above-knee GCS (Australian, ESO).</p>
<p>Antiplatelets are mentioned in most of the guidelines as an adjunct for VTE prophylaxis. The ACCP guidelines state explicitly that aspirin alone is not recommended for thromboprophylaxis; the AHA/ASA state that aspirin is a potential intervention but is less effective than anticoagulants. The Canadian guidelines advocate for antiplatelets to be optimized among other strategies for secondary prevention, whereas the Australian and SIGN guidelines mention antiplatelets specifically as a means to help prevent VTE. Only the SIGN guidelines recommend a specific dose (aspirin 300 mg/d).</p>
<p>All guidelines recommend prophylaxis with antithrombotics in high-risk patients with ischemic stroke; only the SIGN guidelines specifically recommend LMWH over UFH, whereas the others state that either is acceptable.</p>
<p>Those guidelines that address hemorrhagic stroke have conflicting recommendations; only the AHA/ASA guidelines support the use of mechanical methods and explicitly mention the consideration of use of pharmacoprophylaxis after ICH. The Australian guidelines recommend against thigh-high GCS for all patients and against antithrombotic therapy for hemorrhagic stroke explicitly; the Canadian guidelines recommend that mechanical methods be considered in cases of hemorrhagic stroke.</p>
<p>Future guidelines on post-stroke care will need to highlight the importance of mobilization and hydration, update recommendations on mechanical prophylaxis, and provide guidance regarding the role of antithrombotic therapy in hemorrhagic stroke.</p>
</sec>
<sec id="section32-1076029611412362">
<title>Conclusions</title>
<p>Venous thromboembolism after stroke is common and contributes to increased morbidity and mortality, though recent improvements in post-stroke care have reduced its incidence. Intermittent pneumatic compression devices have shown to prevent DVT in small trials underpowered to detect PE. Intermittent pneumatic compression devices are routinely used for mechanical prophylaxis and a large randomized trial investigating their efficacy is underway. Graduated compression stockings do not significantly reduce VTE and are associated with skin breakdown. Unfractionated heparin, LMWH, and danaparoid are acceptable options for chemoprophylaxis, though all are associated with an increased risk of bleeding complications.</p>
<p>No pharmacotherapy has been clearly demonstrated as being clinically superior. Though 2 trials have demonstrated superior efficacy for enoxaparin and danaparoid over UFH in the reduction of VTE, the clinical implications of these trials are less clear. The dose of enoxaparin (40 mg) used in the PREVAIL trial and danaparoid 750 IU bid in the study by Turpie et al represent greater anticoagulant activity than the 5000 IU bid of UFH against which they were compared; both the enoxaparin and danaparoid groups experienced a higher rate of major hemorrhage. Additionally, danaparoid demonstrated no difference in preventing proximal DVT, which is more likely to be clinically evident and carries a higher risk of morbidity and mortality.</p>
<p>Cost may have an impact on the choice of agent: UFH is cheaper but requires twice daily dosing and has a greater potential for side effects. Once-daily dosing of LMWH may be preferable due to reduction in nursing time and patients may prefer 1 needle per day rather than 2.</p>
<p>The role of newer anticoagulants in VTE prophylaxis will need to be clarified by dedicated clinical trials. Hemorrhagic stroke is associated with a higher rate of VTE than ischemic stroke and presents a particular challenge in balancing the benefits of prophylaxis with its risk of iatrogenic hemorrhage. Preliminary evidence suggests that anticoagulation after 24 hours of ICH is well tolerated. Further studies are warranted with regard to chemoprophylaxis in ICH and SAH.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgments</title>
<p>We thank the reviewers for their helpful suggestions.</p>
</ack>
<fn-group>
<fn fn-type="other" id="fn1-1076029611412362">
<p>MDH holds the Heart &amp; Stroke Foundation of Alberta, NWT, NU Professorship in Stroke Research and is an Alberta Innovates-Health Solutions Scholar. TSF conducted the background literature search and primarily wrote the manuscript. MDH provided guidance on structure and content and edited the manuscript.</p>
</fn>
<fn fn-type="conflict" id="fn2-1076029611412362">
<p>The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p>
</fn>
<fn fn-type="financial-disclosure" id="fn3-1076029611412362">
<p>The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: MDH has been funded by the Heart &amp; Stroke Foundation of Alberta, Northwest Territories and Nunavut and by Alberta Innovates Health Solutions. The authors did not receive specific funding for this publication.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-1076029611412362">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jørgensen</surname>
<given-names>HS</given-names>
</name>
<name>
<surname>Nakayama</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Raaschou</surname>
<given-names>HO</given-names>
</name>
<name>
<surname>Olsen</surname>
<given-names>TS.</given-names></name></person-group> <article-title>Recovery of walking function in stroke patients: the Copenhagen stroke study</article-title>. <source>Arch Phys Med Rehabil</source>. <year>1995</year>;<volume>76</volume>(<issue>1</issue>):<fpage>27</fpage>–<lpage>32</lpage>.</citation>
</ref>
<ref id="bibr2-1076029611412362">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jørgensen</surname>
<given-names>HS</given-names>
</name>
<name>
<surname>Nakayama</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Raaschou</surname>
<given-names>HO</given-names>
</name>
<name>
<surname>Vive-Larsen</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Støier</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Olsen</surname>
<given-names>TS.</given-names></name></person-group> <article-title>Outcome and time course of recovery in stroke. Part II: time course of recovery. The Copenhagen Stroke Study</article-title>. <source>Arch Phys Med Rehabil</source>. <year>1995</year>;<volume>76</volume>(<issue>5</issue>):<fpage>406</fpage>–<lpage>412</lpage>.</citation>
</ref>
<ref id="bibr3-1076029611412362">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Collen</surname>
<given-names>FM</given-names>
</name>
<name>
<surname>Wade</surname>
<given-names>DT.</given-names></name></person-group> <article-title>Residual mobility problems after stroke</article-title>. <source>Disabil Rehabil</source>. <year>1991</year>;<volume>13</volume>(<issue>1</issue>):<fpage>12</fpage>–<lpage>15</lpage>.</citation>
</ref>
<ref id="bibr4-1076029611412362">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Montecucco</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Lenglet</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Gayet-Ageron</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>Systemic and intraplaque mediators of inflammation are increased in patients symptomatic for ischemic stroke</article-title>. <source>Stroke</source>. <year>2010</year>;<volume>41</volume>(<issue>7</issue>):<fpage>1394</fpage>–<lpage>1404</lpage>.</citation>
</ref>
<ref id="bibr5-1076029611412362">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sarrafzadeh</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Schlenk</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Gericke</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Vajkoczy</surname>
<given-names>P.</given-names></name></person-group> <article-title>Relevance of cerebral interleukin-6 after aneurysmal subarachnoid hemorrhage [Internet]</article-title>. <source>Neurocrit Care</source>. <year>2010</year>;<volume>13</volume>(<issue>3</issue>):<fpage>339</fpage>–<lpage>346</lpage>.</citation>
</ref>
<ref id="bibr6-1076029611412362">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Silva</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Leira</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Tejada</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Molecular signatures of vascular injury are associated with early growth of intracerebral hemorrhage</article-title>. <source>Stroke</source>. <year>2005</year>;<volume>36</volume>(<issue>1</issue>):<fpage>86</fpage>–<lpage>91</lpage>.</citation>
</ref>
<ref id="bibr7-1076029611412362">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kamphuisen</surname>
<given-names>PW</given-names>
</name>
<name>
<surname>Agnelli</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Sebastianelli</surname>
<given-names>M.</given-names></name></person-group> <article-title>Prevention of venous thromboembolism after acute ischemic stroke</article-title>. <source>J Thromb Haemost</source>. <year>2005</year>;<volume>3</volume>(<issue>6</issue>):<fpage>1187</fpage>–<lpage>1194</lpage>.</citation>
</ref>
<ref id="bibr8-1076029611412362">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Denham</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Farran</surname>
<given-names>H</given-names>
</name>
<name>
<surname>James</surname>
<given-names>G.</given-names></name></person-group> <article-title>The value of 125I fibrinogen in the diagnosis of deep venous thrombosis in hemiplegia</article-title>. <source>Age Ageing</source>. <year>1973</year>;<volume>2</volume>(<issue>4</issue>):<fpage>207</fpage>–<lpage>210</lpage>.</citation>
</ref>
<ref id="bibr9-1076029611412362">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Warlow</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Ogston</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Douglas</surname>
<given-names>AS.</given-names></name></person-group> <article-title>Deep venous thrombosis of the legs after strokes. Part I–incidence and predisposing factors</article-title>. <source>Br Med J</source>. <year>1976</year>;<volume>1</volume>(<issue>6019</issue>):<fpage>1178</fpage>–<lpage>1181</lpage>.</citation>
</ref>
<ref id="bibr10-1076029611412362">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mccarthy</surname>
<given-names>ST</given-names>
</name>
<name>
<surname>Turner</surname>
<given-names>J.</given-names></name></person-group> <article-title>Low-dose subcutaneous heparin in the prevention of deep-vein thrombosis and pulmonary emboli following acute stroke</article-title>. <source>Age Ageing</source>. <year>1986</year>;<volume>15</volume>(<issue>2</issue>):<fpage>841</fpage>–<lpage>888</lpage>.</citation>
</ref>
<ref id="bibr11-1076029611412362">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kearon</surname>
<given-names>C.</given-names></name></person-group> <article-title>Natural history of venous thromboembolism</article-title>. <source>Circulation</source>. <year>2003</year>;<volume>107</volume>(<issue>23 suppl 1</issue>):<fpage>I–22</fpage>–<lpage>I–30</lpage>.</citation>
</ref>
<ref id="bibr12-1076029611412362">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Prins</surname>
<given-names>MH</given-names>
</name>
<name>
<surname>Gelsema</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Sing</surname>
<given-names>AK</given-names>
</name>
<name>
<surname>van Heerde</surname>
<given-names>LR</given-names>
</name>
<name>
<surname>den Ottolander</surname>
<given-names>GJ.</given-names></name></person-group> <article-title>Prophylaxis of deep venous thrombosis with a low-molecular-weight heparin (kabi 2165/fragmin) in stroke patients</article-title>. <source>Haemostasis</source>. <year>1989</year>;<volume>19</volume>(<issue>5</issue>):<fpage>245</fpage>–<lpage>250</lpage>.</citation>
</ref>
<ref id="bibr13-1076029611412362">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sandset</surname>
<given-names>PM</given-names>
</name>
<name>
<surname>Dahl</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Stiris</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Rostad</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Scheel</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Abildgaard</surname>
<given-names>U.</given-names></name></person-group> <article-title>A double-blind and randomized placebo-controlled trial of low molecular weight heparin once daily to prevent deep-vein thrombosis in acute ischemic stroke</article-title>. <source>Semin Thromb Hemost</source>. <year>1990</year>;<volume>16</volume>(<issue>suppl</issue>):<fpage>25</fpage>–<lpage>33</lpage>.</citation>
</ref>
<ref id="bibr14-1076029611412362">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kay</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Wong</surname>
<given-names>KS</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>YL</given-names>
</name>
<etal/>
</person-group>. <article-title>Low-molecular-weight heparin for the treatment of acute ischemic stroke</article-title>. <source>N Engl J Med</source>. <year>1995</year>;<volume>333</volume>(<issue>24</issue>):<fpage>1588</fpage>–<lpage>1593</lpage>.</citation>
</ref>
<ref id="bibr15-1076029611412362">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Sandercock</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Pan</surname>
<given-names>H</given-names>
</name>
<etal/>
</person-group>. <article-title>Indications for early aspirin use in acute ischemic stroke: a combined analysis of 40 000 randomized patients from the chinese acute stroke trial and the international stroke trial</article-title>. <source>Stroke</source>. <year>2000</year>;<volume>31</volume>(<issue>6</issue>):<fpage>1240</fpage>–<lpage>1249</lpage>.</citation>
</ref>
<ref id="bibr16-1076029611412362">
<label>16</label>
<citation citation-type="journal">
<collab collab-type="author">The Publications Committee for the Trial of ORG 10172 in Acute Stroke Treatment Investigators</collab>. <article-title>Low molecular weight heparinoid, ORG 10172 (Danaparoid), and outcome after acute ischemic stroke: a randomized controlled trial</article-title>. <source>JAMA</source>. <year>1998</year>;<volume>279</volume>(<issue>16</issue>):<fpage>1265</fpage>–<lpage>1272</lpage>.</citation>
</ref>
<ref id="bibr17-1076029611412362">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Muir</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Watt</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Baxter</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Grosset</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Lees</surname>
<given-names>K.</given-names></name></person-group> <article-title>Randomized trial of graded compression stockings for prevention of deep—vein thrombosis after acute stroke</article-title>. <source>QJM</source>. <year>2000</year>;<volume>93</volume>(<issue>6</issue>):<fpage>359</fpage>–<lpage>364</lpage>.</citation>
</ref>
<ref id="bibr18-1076029611412362">
<label>18</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kelly</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Rudd</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Lewis</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Coshall</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Moody</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Hunt</surname>
<given-names>B.</given-names></name></person-group> <article-title>Venous thromboembolism after acute ischemic stroke: a prospective study using magnetic resonance direct thrombus imaging</article-title>. <source>Stroke</source>. <year>2004</year>;<volume>35</volume>(<issue>10</issue>):<fpage>2320</fpage>–<lpage>2325</lpage>.</citation>
</ref>
<ref id="bibr19-1076029611412362">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Skaf</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Stein</surname>
<given-names>PD</given-names>
</name>
<name>
<surname>Beemath</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Sanchez</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Bustamante</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Olson</surname>
<given-names>RE.</given-names></name></person-group> <article-title>Venous thromboembolism in patients with ischemic and hemorrhagic stroke</article-title>. <source>Am J Cardiol</source>. <year>2005</year>;<volume>96</volume>(<issue>12</issue>):<fpage>1731</fpage>–<lpage>1733</lpage>.</citation>
</ref>
<ref id="bibr20-1076029611412362">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>De Silva</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Pey</surname>
<given-names>HB</given-names>
</name>
<name>
<surname>Wong</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>HM</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>CP.</given-names></name></person-group> <article-title>Deep vein thrombosis following ischemic stroke among asians</article-title>. <source>Cerebrovasc Dis</source>. <year>2006</year>;<volume>22</volume>(<issue>4</issue>):<fpage>245</fpage>–<lpage>250</lpage>.</citation>
</ref>
<ref id="bibr21-1076029611412362">
<label>21</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tan</surname>
<given-names>SSS</given-names>
</name>
<name>
<surname>Venketasubramanian</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Ong</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Lim</surname>
<given-names>TCC.</given-names></name></person-group> <article-title>Early deep vein thrombosis: incidence in asian stroke patients</article-title>. <source>Ann Acad Med Singap</source>. <year>2007</year>;<volume>36</volume>(<issue>10</issue>):<fpage>815</fpage>–<lpage>820</lpage>.</citation>
</ref>
<ref id="bibr22-1076029611412362">
<label>22</label>
<citation citation-type="journal">. <article-title>Effectiveness of thigh-length graduated compression stockings to reduce the risk of deep vein thrombosis after stroke (CLOTS trial 1): a multicentre, randomised controlled trial</article-title>. <source>Lancet</source>. <year>2009</year>;<volume>373</volume>(<issue>9679</issue>):<fpage>1958</fpage>–<lpage>1965</lpage>.</citation>
</ref>
<ref id="bibr23-1076029611412362">
<label>23</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Diringer</surname>
<given-names>MN</given-names>
</name>
<name>
<surname>Skolnick</surname>
<given-names>BE</given-names>
</name>
<name>
<surname>Mayer</surname>
<given-names>SA</given-names>
</name>
<etal/>
</person-group>. <article-title>Risk of thromboembolic events in controlled trials of rFVIIa in spontaneous intracerebral hemorrhage</article-title>. <source>Stroke</source>. <year>2008</year>;<volume>39</volume>(<issue>3</issue>):<fpage>850</fpage>–<lpage>856</lpage>.</citation>
</ref>
<ref id="bibr24-1076029611412362">
<label>24</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yablon</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Rock</surname>
<given-names>WA</given-names>
</name>
<name>
<surname>Nick</surname>
<given-names>TG</given-names>
</name>
<name>
<surname>Sherer</surname>
<given-names>M</given-names>
</name>
<name>
<surname>McGrath</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Goodson</surname>
<given-names>KH.</given-names></name></person-group> <article-title>Deep vein thrombosis: prevalence and risk factors in rehabilitation admissions with brain injury</article-title>. <source>Neurology</source>. <year>2004</year>;<volume>63</volume>(<issue>3</issue>):<fpage>485</fpage>–<lpage>491</lpage>.</citation>
</ref>
<ref id="bibr25-1076029611412362">
<label>25</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lacut</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Bressollette</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Le Gal</surname>
<given-names>G</given-names>
</name>
<etal/>
</person-group>. <article-title>Prevention of venous thrombosis in patients with acute intracerebral hemorrhage</article-title>. <source>Neurology</source>. <year>2005</year>;<volume>65</volume>(<issue>6</issue>):<fpage>865</fpage>–<lpage>869</lpage>.</citation>
</ref>
<ref id="bibr26-1076029611412362">
<label>26</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kawase</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Okazaki</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Toyoda</surname>
<given-names>K</given-names>
</name>
<etal/>
</person-group>. <article-title>Sex difference in the prevalence of deep-vein thrombosis in Japanese patients with acute intracerebral hemorrhage</article-title>. <source>Cerebrovasc Dis</source>. <year>2009</year>;<volume>27</volume>(<issue>4</issue>):<fpage>313</fpage>–<lpage>319</lpage>.</citation>
</ref>
<ref id="bibr27-1076029611412362">
<label>27</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tonarelli</surname>
<given-names>SB</given-names>
</name>
<name>
<surname>Hart</surname>
<given-names>RG.</given-names></name></person-group> <article-title>Prevention and treatment of venous thromboembolism in patients with acute intracerebral hemorrhage</article-title>. <source>Semin Cerebrovasc Dis Stroke</source>. <year>2005</year>;<volume>5</volume>:<fpage>189</fpage>–<lpage>193</lpage>.</citation>
</ref>
<ref id="bibr28-1076029611412362">
<label>28</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gregory</surname>
<given-names>PC</given-names>
</name>
<name>
<surname>Kuhlemeier</surname>
<given-names>KV.</given-names></name></person-group> <article-title>Prevalence of venous thromboembolism in acute hemorrhagic and thromboembolic stroke</article-title>. <source>Am J Phys Med Rehabil</source>. <year>2003</year>;<volume>82</volume>(<issue>5</issue>):<fpage>364</fpage>–<lpage>369</lpage>.</citation>
</ref>
<ref id="bibr29-1076029611412362">
<label>29</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cohen</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Lewis</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Sandercock</surname>
<given-names>P.</given-names></name></person-group> <article-title>Frequency of death, dependency and pulmonary embolism after haemorrhagic stroke</article-title>. <source>Cerebrovasc Dis</source>. <year>2000</year>;<volume>10</volume>(<issue>suppl 2</issue>):<fpage>52</fpage>.</citation>
</ref>
<ref id="bibr30-1076029611412362">
<label>30</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>André</surname>
<given-names>C</given-names>
</name>
<name>
<surname>de Freitas</surname>
<given-names>GR</given-names>
</name>
<name>
<surname>Fukujima</surname>
<given-names>MM.</given-names></name></person-group> <article-title>Prevention of deep venous thrombosis and pulmonary embolism following stroke: a systematic review of published articles</article-title>. <source>Eur J Neurol</source>. <year>2007</year>;<volume>14</volume>(<issue>1</issue>):<fpage>21</fpage>–<lpage>32</lpage>.</citation>
</ref>
<ref id="bibr31-1076029611412362">
<label>31</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Black</surname>
<given-names>PM</given-names>
</name>
<name>
<surname>Crowell</surname>
<given-names>RM</given-names>
</name>
<name>
<surname>Abbott</surname>
<given-names>WM.</given-names></name></person-group> <article-title>External pneumatic calf compression reduces deep venous thrombosis in patients with ruptured intracranial aneurysms</article-title>. <source>Neurosurgery</source>. <year>1986</year>;<volume>18</volume>(<issue>1</issue>):<fpage>25</fpage>–<lpage>28</lpage>.</citation>
</ref>
<ref id="bibr32-1076029611412362">
<label>32</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mack</surname>
<given-names>WJ</given-names>
</name>
<name>
<surname>Ducruet</surname>
<given-names>AF</given-names>
</name>
<name>
<surname>Hickman</surname>
<given-names>ZL</given-names>
</name>
<etal/>
</person-group>. <article-title>Doppler ultrasonography screening of poor-grade subarachnoid hemorrhage patients increases the diagnosis of deep venous thrombosis</article-title>. <source>Neurol Res</source>. <year>2008</year>;<volume>30</volume>(<issue>9</issue>):<fpage>889</fpage>–<lpage>892</lpage>.</citation>
</ref>
<ref id="bibr33-1076029611412362">
<label>33</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tapaninaho</surname>
<given-names>A.</given-names></name></person-group> <article-title>Deep vein thrombosis after aneurysm surgery</article-title>. <source>Acta Neurochir (Wien)</source>. <year>1985</year>;<volume>74</volume>(<issue>1-2</issue>):<fpage>18</fpage>–<lpage>20</lpage>.</citation>
</ref>
<ref id="bibr34-1076029611412362">
<label>34</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Siironen</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Juvela</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Varis</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>No effect of enoxaparin on outcome of aneurysmal subarachnoid hemorrhage: a randomized, double-blind, placebo-controlled clinical trial</article-title>. <source>J Neurosurg</source>. <year>2003</year>;<volume>99</volume>(<issue>6</issue>):<fpage>953</fpage>–<lpage>959</lpage>.</citation>
</ref>
<ref id="bibr35-1076029611412362">
<label>35</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kelly</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Rudd</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Lewis</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Hunt</surname>
<given-names>BJ.</given-names></name></person-group> <article-title>Venous thromboembolism after acute stroke</article-title>. <source>Stroke</source>. <year>2001</year>;<volume>32</volume>(<issue>1</issue>):<fpage>262</fpage>–<lpage>267</lpage>.</citation>
</ref>
<ref id="bibr36-1076029611412362">
<label>36</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Viitanen</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Winblad</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Asplund</surname>
<given-names>K.</given-names></name></person-group> <article-title>Autopsy-verified causes of death after stroke</article-title>. <source>Acta Med Scand</source>. <year>1987</year>;<volume>222</volume>(<issue>5</issue>):<fpage>401</fpage>–<lpage>408</lpage>.</citation>
</ref>
<ref id="bibr37-1076029611412362">
<label>37</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bounds</surname>
<given-names>JV</given-names>
</name>
<name>
<surname>Wiebers</surname>
<given-names>DO</given-names>
</name>
<name>
<surname>Whisnant</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Okazaki</surname>
<given-names>H.</given-names></name></person-group> <article-title>Mechanisms and timing of deaths from cerebral infarction</article-title>. <source>Stroke</source>. <year>1981</year>;<volume>12</volume>(<issue>4</issue>):<fpage>474</fpage>–<lpage>477</lpage>.</citation>
</ref>
<ref id="bibr38-1076029611412362">
<label>38</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brown</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Glassenberg</surname>
<given-names>M.</given-names></name></person-group> <article-title>Mortality factors in patients with acute stroke</article-title>. <source>JAMA</source>. <year>1973</year>;<volume>224</volume>(<issue>11</issue>):<fpage>1493</fpage>–<lpage>1495</lpage>.</citation>
</ref>
<ref id="bibr39-1076029611412362">
<label>39</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wijdicks</surname>
<given-names>EF</given-names>
</name>
<name>
<surname>Scott</surname>
<given-names>JP.</given-names></name></person-group> <article-title>Pulmonary embolism associated with acute stroke</article-title>. <source>Mayo Clin Proc</source>. <year>1997</year>;<volume>72</volume>(<issue>4</issue>):<fpage>297</fpage>–<lpage>300</lpage>.</citation>
</ref>
<ref id="bibr40-1076029611412362">
<label>40</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Turpie</surname>
<given-names>AG</given-names>
</name>
<name>
<surname>Levine</surname>
<given-names>MN</given-names>
</name>
<name>
<surname>Hirsh</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Double-blind randomised trial of Org 10172 low-molecular-weight heparinoid in prevention of deep-vein thrombosis in thrombotic stroke</article-title>. <source>Lancet</source>. <year>1987</year>;<volume>1</volume>(<issue>8532</issue>):<fpage>523</fpage>–<lpage>526</lpage>.</citation>
</ref>
<ref id="bibr41-1076029611412362">
<label>41</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Boeer</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Voth</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Henze</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Prange</surname>
<given-names>HW.</given-names></name></person-group> <article-title>Early heparin therapy in patients with spontaneous intracerebral haemorrhage</article-title>. <source>J Neurol Neurosurg Psychiatry</source>. <year>1991</year>;<volume>54</volume>(<issue>5</issue>):<fpage>466</fpage>–<lpage>467</lpage>.</citation>
</ref>
<ref id="bibr42-1076029611412362">
<label>42</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Landi</surname>
<given-names>G</given-names>
</name>
<name>
<surname>D’Angelo</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Boccardi</surname>
<given-names>E</given-names>
</name>
<etal/>
</person-group>. <article-title>Venous thromboembolism in acute stroke. Prognostic importance of hypercoagulability</article-title>. <source>Arch Neurol</source>. <year>1992</year>;<volume>49</volume>(<issue>3</issue>):<fpage>279</fpage>–<lpage>283</lpage>.</citation>
</ref>
<ref id="bibr43-1076029611412362">
<label>43</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>LaBresh</surname>
<given-names>KA</given-names>
</name>
<name>
<surname>Reeves</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Frankel</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Albright</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Schwamm</surname>
<given-names>LH.</given-names></name></person-group> <article-title>Hospital treatment of patients with ischemic stroke or transient ischemic attack using the “get with the guidelines” program</article-title>. <source>Arch Intern Med</source>. <year>2008</year>;<volume>168</volume>(<issue>4</issue>):<fpage>411</fpage>–<lpage>417</lpage>.</citation>
</ref>
<ref id="bibr44-1076029611412362">
<label>44</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Harvey</surname>
<given-names>RJ.</given-names></name></person-group> <article-title>Prevention of venous thromboembolism after stroke</article-title>. <source>Top Stroke Rehabil</source>. <year>2003</year>;<volume>10</volume>(<issue>3</issue>):<fpage>61</fpage>–<lpage>69</lpage>.</citation>
</ref>
<ref id="bibr45-1076029611412362">
<label>45</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Muir</surname>
<given-names>KW.</given-names></name></person-group> <article-title>The PREVAIL trial and low-molecular-weight heparin for prevention of venous thromboembolism</article-title>. <source>Stroke</source>. <year>2008</year>;<volume>39</volume>(<issue>7</issue>):<fpage>2174</fpage>–<lpage>2176</lpage>.</citation>
</ref>
<ref id="bibr46-1076029611412362">
<label>46</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lamb</surname>
<given-names>GC</given-names>
</name>
<name>
<surname>Tomski</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Kaufman</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Maiman</surname>
<given-names>DJ.</given-names></name></person-group> <article-title>Is chronic spinal cord injury associated with increased risk of venous thromboembolism?</article-title>. <source>J Am Paraplegia Soc</source>. <year>1993</year>;<volume>16</volume>(<issue>3</issue>):<fpage>153</fpage>–<lpage>156</lpage>.</citation>
</ref>
<ref id="bibr47-1076029611412362">
<label>47</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Langhorne</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Pollock</surname>
<given-names>A.</given-names></name></person-group> <article-title>What are the components of effective stroke unit care?</article-title>. <source>Age Ageing</source>. <year>2002</year>;<volume>31</volume>(<issue>5</issue>):<fpage>365</fpage>–<lpage>371</lpage>.</citation>
</ref>
<ref id="bibr48-1076029611412362">
<label>48</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Adams</surname>
<given-names>HP</given-names>
</name>
<name>
<surname>Del Zoppo</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Alberts</surname>
<given-names>MJ</given-names>
</name>
<etal/>
</person-group>. <article-title>Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists</article-title>. <source>Stroke</source>. <year>2007</year>;<volume>38</volume>(<issue>5</issue>):<fpage>1655</fpage>–<lpage>1711</lpage>.</citation>
</ref>
<ref id="bibr49-1076029611412362">
<label>49</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lindsay</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Bayley</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Hellings</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Hill</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Woodbury</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Phillips</surname>
<given-names>S</given-names>
</name>
</person-group>
<collab collab-type="author">(Canadian Stroke Strategy Best Practices and Standards Writing Group on behalf of the Canadian Stroke Strategy)</collab>. <article-title>Canadian best practice recommendations for stroke care (updated 2008)</article-title>. <source>CMAJ</source>. <year>2008</year>;<volume>179</volume>(<issue>12</issue>):<fpage>S1</fpage>–<lpage>S25</lpage>.</citation>
</ref>
<ref id="bibr50-1076029611412362">
<label>50</label>
<citation citation-type="web">
<collab collab-type="author">National Stroke Foundation–Australia</collab>. <article-title>Clinical Guidelines for Stroke Management 2010</article-title>. <ext-link ext-link-type="uri" xlink:href="http://www.strokefoundation.com.au/clinical-guidelines">http://www.strokefoundation.com.au/clinical-guidelines</ext-link>. <comment>Accessed January 30, 2011</comment>.</citation>
</ref>
<ref id="bibr51-1076029611412362">
<label>51</label>
<citation citation-type="web">
<collab collab-type="author">The European Stroke Organisation (ESO) Executive Committee and the ESO Writing Committee</collab>. <article-title>Guidelines for management of ischaemic stroke and transient ischaemic attack 2009</article-title>. <ext-link ext-link-type="uri" xlink:href="http://www.eso-stroke.org/recommendations.php?cid=9&amp;sid=1">http://www.eso-stroke.org/recommendations.php?cid=9&amp;sid=1</ext-link>. <comment>Accessed January 30, 2011</comment>.</citation>
</ref>
<ref id="bibr52-1076029611412362">
<label>52</label>
<citation citation-type="web">
<collab collab-type="author">Scottish Intercollegiate Guidelines Network</collab>. <article-title>Management of Patients with Stroke Rehabilitation, Prevention and Management of Complications, and Discharge Planning A national clinical guideline</article-title>. <month>June</month> <year>2010</year>. <ext-link ext-link-type="uri" xlink:href="http://www.sign.ac.uk/guidelines/fulltext/118/index.html">http://www.sign.ac.uk/guidelines/fulltext/118/index.html</ext-link>. <comment>Accessed January 30, 2011</comment>.</citation></ref>
<ref id="bibr53-1076029611412362">
<label>53</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Geerts</surname>
<given-names>WH</given-names>
</name>
<name>
<surname>Bergqvist</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Pineo</surname>
<given-names>GF</given-names>
</name>
<name>
<surname>Heit</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Samama</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Lassen</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Colwell</surname>
<given-names>CW.</given-names></name></person-group> <article-title>Prevention of Venous Thromboembolism*</article-title>. <source>Chest</source>. <year>2008</year>;<volume>133</volume>(<issue>6 suppl</issue>):<fpage>381S</fpage>–<lpage>453S</lpage>.</citation>
</ref>
<ref id="bibr54-1076029611412362">
<label>54</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cumming</surname>
<given-names>TB</given-names>
</name>
<name>
<surname>Collier</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Thrift</surname>
<given-names>AG</given-names>
</name>
<name>
<surname>Bernhardt</surname>
<given-names>J.</given-names></name></person-group> <article-title>The effect of very early mobilisation after stroke on psychological well-being</article-title>. <source>J Rehabil Med</source>. <year>2008</year>;<volume>40</volume>(<issue>8</issue>):<fpage>609</fpage>–<lpage>614</lpage>.</citation>
</ref>
<ref id="bibr55-1076029611412362">
<label>55</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Langhorne</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Stott</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Knight</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Bernhardt</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Barer</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Watkins</surname>
<given-names>C.</given-names></name></person-group> <article-title>Very early rehabilitation or intensive telemetry after stroke: a pilot randomised trial</article-title>. <source>Cerebrovasc Dis</source>. <year>2010</year>;<volume>29</volume>(<issue>4</issue>):<fpage>352</fpage>–<lpage>360</lpage>.</citation>
</ref>
<ref id="bibr56-1076029611412362">
<label>56</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kelly</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Hunt</surname>
<given-names>BJ</given-names>
</name>
<name>
<surname>Lewis</surname>
<given-names>RR</given-names>
</name>
<etal/>
</person-group>. <article-title>Dehydration and venous thromboembolism after acute stroke</article-title>. <source>QJM</source>. <year>2004</year>;<volume>97</volume>(<issue>5</issue>):<fpage>293</fpage>–<lpage>296</lpage>.</citation>
</ref>
<ref id="bibr57-1076029611412362">
<label>57</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bhalla</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Sankaralingam</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Dundas</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Swaminathan</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Wolfe</surname>
<given-names>CDA</given-names>
</name>
<name>
<surname>Rudd</surname>
<given-names>AG.</given-names></name></person-group> <article-title>Influence of raised plasma osmolality on clinical outcome after acute stroke</article-title>. <source>Stroke</source>. <year>2000</year>;<volume>31</volume>(<issue>9</issue>):<fpage>2043</fpage>–<lpage>2048</lpage>.</citation>
</ref>
<ref id="bibr58-1076029611412362">
<label>58</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kay</surname>
<given-names>TW</given-names>
</name>
<name>
<surname>Martin</surname>
<given-names>FI.</given-names></name></person-group> <article-title>Heel ulcers in patients with long-standing diabetes who wear antiembolism stockings</article-title>. <source>Med J Aust</source>. <year>1986</year>;<volume>145</volume>(<issue>6</issue>):<fpage>290</fpage>–<lpage>291</lpage>.</citation>
</ref>
<ref id="bibr59-1076029611412362">
<label>59</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Merrett</surname>
<given-names>ND</given-names>
</name>
<name>
<surname>Hanel</surname>
<given-names>KC.</given-names></name></person-group> <article-title>Ischaemic complications of graduated compression stockings in the treatment of deep venous thrombosis</article-title>. <source>Postgrad Med J</source>. <year>1993</year>;<volume>69</volume>(<issue>809</issue>):<fpage>232</fpage>–<lpage>234</lpage>.</citation>
</ref>
<ref id="bibr60-1076029611412362">
<label>60</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Doran</surname>
<given-names>FSA</given-names>
</name>
<name>
<surname>White</surname>
<given-names>HM.</given-names></name></person-group> <article-title>A demonstration that the risk of postoperative deep venous thrombosis is reduced by stimulating the calf muscles electrically during the operation</article-title>. <source>Br J Surg</source>. <year>1967</year>;<volume>54</volume>(<issue>8</issue>):<fpage>686</fpage>–<lpage>689</lpage>.</citation>
</ref>
<ref id="bibr61-1076029611412362">
<label>61</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nicolaides</surname>
<given-names>AN</given-names>
</name>
<name>
<surname>Kakkar</surname>
<given-names>VV</given-names>
</name>
<name>
<surname>Field</surname>
<given-names>ES</given-names>
</name>
<name>
<surname>Fish</surname>
<given-names>P.</given-names></name></person-group> <article-title>Optimal electrical stimulus for prevention of deep vein thrombosis</article-title>. <source>Br Med J</source>. <year>1972</year>;<volume>3</volume>(<issue>5829</issue>):<fpage>756</fpage>–<lpage>758</lpage>.</citation>
</ref>
<ref id="bibr62-1076029611412362">
<label>62</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lindström</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Holmdahl</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Jonsson</surname>
<given-names>O</given-names>
</name>
<etal/>
</person-group>. <article-title>Prediction and prophylaxis of postoperative thromboembolism–a comparison between peroperative calf muscle stimulation with groups of impulses and dextran 40</article-title>. <source>Br J Surg</source>. <year>1982</year>;<volume>69</volume>(<issue>11</issue>):<fpage>633</fpage>–<lpage>637</lpage>.</citation>
</ref>
<ref id="bibr63-1076029611412362">
<label>63</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rosenberg</surname>
<given-names>IL</given-names>
</name>
<name>
<surname>Evans</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Pollock</surname>
<given-names>AV.</given-names></name></person-group> <article-title>Prophylaxis of postoperative leg vine thrombosis by low dose subcutaneous heparin or peroperative calf muscle stimulation: a controlled clinical trial</article-title>. <source>Br Med J</source>. <year>1975</year>;<volume>1</volume>(<issue>5959</issue>):<fpage>649</fpage>–<lpage>651</lpage>.</citation>
</ref>
<ref id="bibr64-1076029611412362">
<label>64</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Merli</surname>
<given-names>GJ</given-names>
</name>
<name>
<surname>Herbison</surname>
<given-names>GJ</given-names>
</name>
<name>
<surname>Ditunno</surname>
<given-names>JF</given-names>
</name>
<etal/>
</person-group>. <article-title>Deep vein thrombosis: prophylaxis in acute spinal cord injured patients</article-title>. <source>Arch Phys Med Rehabil</source>. <year>1988</year>;<volume>69</volume>(<issue>9</issue>):<fpage>661</fpage>–<lpage>664</lpage>.</citation>
</ref>
<ref id="bibr65-1076029611412362">
<label>65</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Velmahos</surname>
<given-names>GC</given-names>
</name>
<name>
<surname>Petrone</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Chan</surname>
<given-names>LS</given-names>
</name>
<name>
<surname>Hanks</surname>
<given-names>SE</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>CV</given-names>
</name>
<name>
<surname>Demetriades</surname>
<given-names>D.</given-names></name></person-group> <article-title>Electrostimulation for the prevention of deep venous thrombosis in patients with major trauma: a prospective randomized study</article-title>. <source>Surgery</source>. <year>2005</year>;<volume>137</volume>(<issue>5</issue>):<fpage>493</fpage>–<lpage>498</lpage>.</citation>
</ref>
<ref id="bibr66-1076029611412362">
<label>66</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pambianco</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Orchard</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Landau</surname>
<given-names>P.</given-names></name></person-group> <article-title>Deep vein thrombosis: prevention in stroke patients during rehabilitation</article-title>. <source>Arch Phys Med Rehabil</source>. <year>1995</year>;<volume>76</volume>(<issue>4</issue>):<fpage>324</fpage>–<lpage>330</lpage>.</citation>
</ref>
<ref id="bibr67-1076029611412362">
<label>67</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kaplan</surname>
<given-names>RE</given-names>
</name>
<name>
<surname>Czyrny</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Fung</surname>
<given-names>TS</given-names>
</name>
<name>
<surname>Unsworth</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Hirsh</surname>
<given-names>J.</given-names></name></person-group> <article-title>Electrical foot stimulation and implications for the prevention of venous thromboembolic disease</article-title>. <source>Thromb Haemost</source>. <year>2002</year>;<volume>88</volume>(<issue>2</issue>):<fpage>200</fpage>–<lpage>204</lpage>.</citation>
</ref>
<ref id="bibr68-1076029611412362">
<label>68</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Griffin</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Nicolaides</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Bond</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Geroulakos</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Kalodiki</surname>
<given-names>E.</given-names></name></person-group> <article-title>The efficacy of a new stimulation technology to increase venous flow and prevent venous stasis</article-title>. <source>Eur J Vasc Endovasc Surg</source>. <year>2010</year>;<volume>40</volume>(<issue>6</issue>):<fpage>766</fpage>–<lpage>771</lpage>.</citation>
</ref>
<ref id="bibr69-1076029611412362">
<label>69</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sachdeva</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Dalton</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Amarigi</surname>
<given-names>SV</given-names>
</name>
<name>
<surname>Lees</surname>
<given-names>T.</given-names></name></person-group> <article-title>Elastic compression stockings for prevention of deep vein thrombosis</article-title>. <source>Cochrane Database Syst Rev</source>. <year>2010</year>;<volume>7</volume>(<issue>7</issue>):<fpage>CD001484</fpage>.</citation>
</ref>
<ref id="bibr70-1076029611412362">
<label>70</label>
<citation citation-type="book">
<comment>CLOTS-3 protocol, unpublished data. [date unknown]</comment>.</citation>
</ref>
<ref id="bibr71-1076029611412362">
<label>71</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lurie</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Scott</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Yoon</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Kistner</surname>
<given-names>RL.</given-names></name></person-group> <article-title>On the mechanism of action of pneumatic compression devices: combined magnetic resonance imaging and duplex ultrasound investigation</article-title>. <source>J Vasc Surg</source>. <year>2008</year>;<volume>48</volume>(<issue>4</issue>):<fpage>1000</fpage>–<lpage>1006</lpage>.</citation>
</ref>
<ref id="bibr72-1076029611412362">
<label>72</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ljungnér</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Bergqvist</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Nilsson</surname>
<given-names>IM.</given-names></name></person-group> <article-title>Effect of intermittent pneumatic and graduated static compression on factor VIII and the fibrinolytic system</article-title>. <source>Acta Chir Scand</source>. <year>1981</year>;<volume>147</volume>(<issue>8</issue>):<fpage>657</fpage>–<lpage>661</lpage>.</citation>
</ref>
<ref id="bibr73-1076029611412362">
<label>73</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kessler</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Hirsch</surname>
<given-names>DR</given-names>
</name>
<name>
<surname>Jacobs</surname>
<given-names>H</given-names>
</name>
<name>
<surname>MacDougall</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Goldhaber</surname>
<given-names>SZ.</given-names></name></person-group> <article-title>Intermittent pneumatic compression in chronic venous insufficiency favorably affects fibrinolytic potential and platelet activation</article-title>. <source>Blood Coagul Fibrinolysis</source>. <year>1996</year>;<volume>7</volume>(<issue>4</issue>):<fpage>437</fpage>–<lpage>446</lpage>.</citation>
</ref>
<ref id="bibr74-1076029611412362">
<label>74</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Comerota</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Chouhan</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Harada</surname>
<given-names>RN</given-names>
</name>
<etal/>
</person-group>. <article-title>The fibrinolytic effects of intermittent pneumatic compression: mechanism of enhanced fibrinolysis</article-title>. <source>Ann Surg</source>. <year>1997</year>;<volume>226</volume>(<issue>3</issue>):<fpage>306</fpage>–<lpage>313</lpage>. <comment>discussion 313–314</comment>.</citation>
</ref>
<ref id="bibr75-1076029611412362">
<label>75</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chouhan</surname>
<given-names>VD</given-names>
</name>
<name>
<surname>Comerota</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Harada</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Gaughan</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Rao</surname>
<given-names>AK.</given-names></name></person-group> <article-title>Inhibition of tissue factor pathway during intermittent pneumatic compression: a possible mechanism for antithrombotic effect</article-title>. <source>Arterioscler Thromb Vasc Biol</source>. <year>1999</year>;<volume>19</volume>(<issue>11</issue>):<fpage>2812</fpage>–<lpage>2817</lpage>.</citation>
</ref>
<ref id="bibr76-1076029611412362">
<label>76</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Giddings</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Morris</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Ralis</surname>
<given-names>HM</given-names>
</name>
<name>
<surname>Jennings</surname>
<given-names>GM</given-names>
</name>
<name>
<surname>Davies</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Woodcock</surname>
<given-names>JP.</given-names></name></person-group> <article-title>Systemic haemostasis after intermittent pneumatic compression. Clues for the investigation of DVT prophylaxis and travellers thrombosis</article-title>. <source>Clin Lab Haematol</source>. <year>2004</year>;<volume>26</volume>(<issue>4</issue>):<fpage>269</fpage>–<lpage>273</lpage>.</citation>
</ref>
<ref id="bibr77-1076029611412362">
<label>77</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kohro</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Yamakage</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Sato</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Sato</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Namiki</surname>
<given-names>A.</given-names></name></person-group> <article-title>Intermittent pneumatic foot compression can activate blood fibrinolysis without changes in blood coagulability and platelet activation</article-title>. <source>Acta Anaesthesiol Scand</source>. <year>2005</year>;<volume>49</volume>(<issue>5</issue>):<fpage>660</fpage>–<lpage>664</lpage>.</citation>
</ref>
<ref id="bibr78-1076029611412362">
<label>78</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Urbankova</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Quiroz</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Kucher</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Goldhaber</surname>
<given-names>SZ.</given-names></name></person-group> <article-title>Intermittent pneumatic compression and deep vein thrombosis prevention. a meta-analysis in postoperative patients</article-title>. <source>Thromb Haemost</source>. <year>2005</year>;<volume>94</volume>:<fpage>1181</fpage>–<lpage>1185</lpage>.</citation>
</ref>
<ref id="bibr79-1076029611412362">
<label>79</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Prasad</surname>
<given-names>BK</given-names>
</name>
<name>
<surname>Banerjee</surname>
<given-names>AK</given-names>
</name>
<name>
<surname>Howard</surname>
<given-names>H.</given-names></name></person-group> <article-title>Incidence of deep vein thrombosis and the effect of pneumatic compression of the calf in elderly hemiplegics</article-title>. <source>Age Ageing</source>. <year>1982</year>;<volume>11</volume>(<issue>1</issue>):<fpage>42</fpage>–<lpage>44</lpage>.</citation>
</ref>
<ref id="bibr80-1076029611412362">
<label>80</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Collen</surname>
<given-names>JF</given-names>
</name>
<name>
<surname>Jackson</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Shorr</surname>
<given-names>AF</given-names>
</name>
<name>
<surname>Moores</surname>
<given-names>LK.</given-names></name></person-group> <article-title>Prevention of venous thromboembolism in neurosurgery: a metaanalysis</article-title>. <source>Chest</source>. <year>2007</year>;<volume>134</volume>(<issue>2</issue>):<fpage>237</fpage>–<lpage>249</lpage>.</citation>
</ref>
<ref id="bibr81-1076029611412362">
<label>81</label>
<citation citation-type="web">
<collab collab-type="author">CLOTS-3 trial</collab>. <ext-link ext-link-type="uri" xlink:href="www.clinicaltrials.gov">www.clinicaltrials.gov</ext-link> <comment>NCT 00789542. Accessed January, 2011</comment>.</citation>
</ref>
<ref id="bibr82-1076029611412362">
<label>82</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Collaboration</surname>
<given-names>AT.</given-names></name></person-group> <article-title>Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients</article-title>. <source>BMJ</source>. <year>2002</year>;<volume>324</volume>(<issue>7329</issue>):<fpage>71</fpage>–<lpage>86</lpage>.</citation>
</ref>
<ref id="bibr83-1076029611412362">
<label>83</label>
<citation citation-type="journal">
<collab collab-type="author">Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin</collab>: <article-title>pulmonary Embolism Prevention (PEP) trial</article-title>. <source>Lancet</source>. <year>2000</year>;<volume>355</volume>(<issue>9212</issue>):<fpage>1295</fpage>–<lpage>1302</lpage>.</citation>
</ref>
<ref id="bibr84-1076029611412362">
<label>84</label>
<citation citation-type="journal">
<collab collab-type="author">The International Stroke Trial (IST)</collab>: <article-title>a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke</article-title>. <source>Lancet</source>. <year>1997</year>;<volume>349</volume>(<issue>9065</issue>):<fpage>1569</fpage>–<lpage>1581</lpage>.</citation>
</ref>
<ref id="bibr85-1076029611412362">
<label>85</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sandercock</surname>
<given-names>PAG</given-names>
</name>
<name>
<surname>Counsell</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Gubitz</surname>
<given-names>GJ</given-names>
</name>
<name>
<surname>Tseng</surname>
<given-names>MC.</given-names></name></person-group> <article-title>Antiplatelet therapy for acute ischaemic stroke (Review)</article-title>. <source>Cochrane Database Syst Rev</source>. <year>2008</year>;<volume>3</volume>:<fpage>CD000029</fpage>.</citation>
</ref>
<ref id="bibr86-1076029611412362">
<label>86</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Berge</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Abdelnoor</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Nakstad</surname>
<given-names>PH</given-names>
</name>
<name>
<surname>Sandset</surname>
<given-names>PM.</given-names></name></person-group> <article-title>Low molecular-weight heparin versus aspirin in patients with acute ischaemic stroke and atrial fibrillation: a double-blind randomised study. HAEST Study Group. Heparin in Acute Embolic Stroke Trial</article-title>. <source>Lancet</source>. <year>2000</year>;<volume>355</volume>(<issue>9211</issue>):<fpage>1205</fpage>–<lpage>1210</lpage>.</citation>
</ref>
<ref id="bibr87-1076029611412362">
<label>87</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sandercock</surname>
<given-names>PAG</given-names>
</name>
<name>
<surname>Counsell</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Tseng</surname>
<given-names>M.</given-names></name></person-group> <article-title>Low-molecular-weight heparins or heparinoids versus standard unfractionated heparin for acute ischaemic stroke</article-title>. <source>Cochrane Database Syst Rev</source>. <year>2008</year>;<volume>3</volume>:<fpage>CD000119</fpage>.
</citation>
</ref>
<ref id="bibr88-1076029611412362">
<label>88</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bath</surname>
<given-names>PM</given-names>
</name>
<name>
<surname>Lindenstrom</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Boysen</surname>
<given-names>G</given-names>
</name>
<etal/>
</person-group>. <article-title>Tinzaparin in acute ischaemic stroke (TAIST): a randomised aspirin-controlled trial</article-title>. <source>Lancet</source>. <year>2001</year>;<volume>358</volume>(<issue>9283</issue>):<fpage>702</fpage>–<lpage>710</lpage>.</citation>
</ref>
<ref id="bibr89-1076029611412362">
<label>89</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Melero</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Bergroth</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Contardo</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Mazzei</surname>
<given-names>MM.</given-names></name></person-group> <article-title>Prevention of venous thromboembolism after acute ischaemic stroke</article-title>. <source>Lancet</source>. <year>2007</year>;<volume>370</volume>(<issue>9589</issue>):<fpage>735</fpage>–<lpage>735</lpage>.</citation>
</ref>
<ref id="bibr90-1076029611412362">
<label>90</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Diener</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Ringelstein</surname>
<given-names>EB</given-names>
</name>
<name>
<surname>von Kummer</surname>
<given-names>R</given-names>
</name>
<etal/>
</person-group>. <article-title>Prophylaxis of thrombotic and embolic events in acute ischemic stroke with the low-molecular-weight heparin certoparin: results of the PROTECT trial</article-title>. <source>Stroke</source>. <year>2006</year>;<volume>37</volume>(<issue>1</issue>):<fpage>139</fpage>–<lpage>144</lpage>.</citation>
</ref>
<ref id="bibr91-1076029611412362">
<label>91</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Turpie</surname>
<given-names>AG</given-names>
</name>
<name>
<surname>Gent</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Côte</surname>
<given-names>R</given-names>
</name>
<etal/>
</person-group>. <article-title>A low-molecular-weight heparinoid compared with unfractionated heparin in the prevention of deep vein thrombosis in patients with acute ischemic stroke. a randomized, double-blind study</article-title>. <source>Ann Intern Med</source>. <year>1992</year>;<volume>117</volume>(<issue>5</issue>):<fpage>353</fpage>–<lpage>357</lpage>.</citation>
</ref>
<ref id="bibr92-1076029611412362">
<label>92</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Salazar</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Malaga</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Malasquez</surname>
<given-names>G.</given-names></name></person-group> <article-title>Direct thrombin inhibitors versus vitamin K antagonists or low molecular weight heparins for prevention of venous thromboembolism following total hip or knee replacement</article-title>. <source>Cochrane Database Syst Rev</source>. <year>2010</year>;<volume>4</volume>:<fpage>CD005981</fpage>.</citation>
</ref>
<ref id="bibr93-1076029611412362">
<label>93</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sandercock</surname>
<given-names>PAG</given-names>
</name>
<name>
<surname>Counsell</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Kamal</surname>
<given-names>AK.</given-names></name></person-group> <article-title>Anticoagulants for acute ischaemic stroke</article-title>. <source>Cochrane Database Syst Rev</source>. <year>2008</year>;<volume>4</volume>:<fpage>CD000024</fpage>.
</citation>
</ref>
<ref id="bibr94-1076029611412362">
<label>94</label>
<citation citation-type="web">
<person-group person-group-type="author">
<name><surname>Leung</surname><given-names>Lawrence LK.</given-names></name></person-group> <article-title>Anticoagulants other than heparin and warfarin</article-title>. <ext-link ext-link-type="uri" xlink:href="www.uptodate.com">www.uptodate.com</ext-link>. <comment>Accessed September 21, 2010</comment>.</citation>
</ref>
<ref id="bibr95-1076029611412362">
<label>95</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sherman</surname>
<given-names>DG</given-names>
</name>
<name>
<surname>Albers</surname>
<given-names>GW</given-names>
</name>
<name>
<surname>Bladin</surname>
<given-names>C</given-names>
</name>
<etal/>
</person-group>. <article-title>The efficacy and safety of enoxaparin versus unfractionated heparin for the prevention of venous thromboembolism after acute ischaemic stroke (PREVAIL Study): an open-label randomised comparison</article-title>. <source>Lancet</source>. <year>2007</year>;<volume>369</volume>(<issue>9570</issue>):<fpage>1347</fpage>–<lpage>1355</lpage>.</citation>
</ref>
<ref id="bibr96-1076029611412362">
<label>96</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hillbom</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Erila</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Sotaniemi</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Tatlisumak</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Sarna</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kaste</surname>
<given-names>M.</given-names></name></person-group> <article-title>Enoxaparin vs heparin for prevention of deep-vein thrombosis in acute ischaemic stroke: a randomized, double-blind study</article-title>. <source>Acta Neurol Scand</source>. <year>2002</year>;<volume>106</volume>(<issue>2</issue>):<fpage>84</fpage>–<lpage>92</lpage>.</citation>
</ref>
<ref id="bibr97-1076029611412362">
<label>97</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ricci</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Celani</surname>
<given-names>MG</given-names>
</name>
<name>
<surname>Righetti</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Dennis</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Sandercock</surname>
<given-names>P.</given-names></name></person-group> <article-title>Prevention of venous thromboembolism after acute ischaemic stroke</article-title>. <source>Lancet</source>. <year>2007</year>;<volume>370</volume>(<issue>9589</issue>):<fpage>735</fpage>–<lpage>736</lpage>. <comment>author reply 736–737</comment>
</citation>
</ref>
<ref id="bibr98-1076029611412362">
<label>98</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dumas</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Woitinas</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Kutnowski</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>A multicentre, double-blind, randomized study to compare the safety and efficacy of once-daily ORG 10172 and twice-daily low-dose heparin in preventing deep-vein thrombosis in patients with acute ischaemic stroke</article-title>. <source>Age Ageing</source>. <year>1994</year>;<volume>23</volume>(<issue>6</issue>):<fpage>512</fpage>–<lpage>516</lpage>.</citation>
</ref>
<ref id="bibr99-1076029611412362">
<label>99</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Smith</surname>
<given-names>EE</given-names>
</name>
<name>
<surname>Liang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Hernandez</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>Influence of stroke subtype on quality of care in the get with the guidelines–stroke program</article-title>. <source>Neurology</source>. <year>2009</year>;<volume>73</volume>(<issue>9</issue>):<fpage>709</fpage>–<lpage>716</lpage>.</citation>
</ref>
<ref id="bibr100-1076029611412362">
<label>100</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Broderick</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Diringer</surname>
<given-names>MN</given-names>
</name>
<name>
<surname>Hill</surname>
<given-names>MD</given-names>
</name>
<etal/>
</person-group>. <article-title>Determinants of intracerebral hemorrhage growth: an exploratory analysis</article-title>. <source>Stroke</source>. <year>2007</year>;<volume>38</volume>(<issue>3</issue>):<fpage>1072</fpage>–<lpage>1075</lpage>.</citation>
</ref>
<ref id="bibr101-1076029611412362">
<label>101</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dickmann</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Voth</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Schicha</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Henze</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Prange</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Emrich</surname>
<given-names>D.</given-names></name></person-group> <article-title>Heparin therapy, deep-vein thrombosis and pulmonary embolism after intracerebral hemorrhage</article-title>. <source>Klin Wochenschr</source>. <year>1988</year>;<volume>66</volume>(<issue>23</issue>):<fpage>1182</fpage>–<lpage>1183</lpage>.</citation>
</ref>
<ref id="bibr102-1076029611412362">
<label>102</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Orken</surname>
<given-names>DN</given-names>
</name>
<name>
<surname>Kenangil</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Ozkurt</surname>
<given-names>H</given-names>
</name>
<etal/>
</person-group>. <article-title>Prevention of deep venous thrombosis and pulmonary embolism in patients with acute intracerebral hemorrhage</article-title>. <source>Neurologist</source>. <year>2009</year>;<volume>15</volume>(<issue>6</issue>):<fpage>329</fpage>–<lpage>331</lpage>.</citation>
</ref>
<ref id="bibr103-1076029611412362">
<label>103</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tetri</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Hakala</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Juvela</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Safety of low-dose subcutaneous enoxaparin for the prevention of venous thromboembolism after primary intracerebral haemorrhage</article-title>. <source>Thrombosis Res</source>. <year>2008</year>;<volume>123</volume>(<issue>2</issue>):<fpage>206</fpage>–<lpage>212</lpage>.</citation>
</ref>
<ref id="bibr104-1076029611412362">
<label>104</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kiphuth</surname>
<given-names>IC</given-names>
</name>
<name>
<surname>Staykov</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Köhrmann</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Early administration of low molecular weight heparin after spontaneous intracerebral hemorrhage. a safety analysis</article-title>. <source>Cerebrovasc Dis</source>. <year>2009</year>;<volume>27</volume>(<issue>2</issue>):<fpage>146</fpage>–<lpage>150</lpage>.</citation>
</ref>
<ref id="bibr105-1076029611412362">
<label>105</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Kasam</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Harun</surname>
<given-names>N</given-names>
</name>
<etal/>
</person-group>. <article-title>Pharmacological deep vein thrombosis prophylaxis does not lead to hematoma expansion in intracerebral Hemorrhage with intraventricular extension</article-title>. <source>Stroke</source>. <year>2011</year>;<volume>42</volume>(<issue>3</issue>):<fpage>705</fpage>–<lpage>709</lpage>.</citation>
</ref>
<ref id="bibr106-1076029611412362">
<label>106</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ray</surname>
<given-names>WZ</given-names>
</name>
<name>
<surname>Strom</surname>
<given-names>RG</given-names>
</name>
<name>
<surname>Blackburn</surname>
<given-names>SL</given-names>
</name>
<name>
<surname>Ashley</surname>
<given-names>WW</given-names>
</name>
<name>
<surname>Sicard</surname>
<given-names>GA</given-names>
</name>
<name>
<surname>Rich</surname>
<given-names>KM.</given-names></name></person-group> <article-title>Incidence of deep venous thrombosis after subarachnoid hemorrhage</article-title>. <source>J Neurosurg</source>. <year>2009</year>;<volume>110</volume>(<issue>5</issue>):<fpage>1010</fpage>–<lpage>1014</lpage>.</citation>
</ref>
<ref id="bibr107-1076029611412362">
<label>107</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sen</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Belli</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Albon</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Morgan</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Petzold</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kitchen</surname>
<given-names>N.</given-names></name></person-group> <article-title>Triple-H therapy in the management of aneurysmal subarachnoid haemorrhage</article-title>. <source>Lancet Neurol</source>. <year>2003</year>;<volume>2</volume>(<issue>10</issue>):<fpage>614</fpage>–<lpage>621</lpage>.</citation></ref></ref-list>
</back>
</article>